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The Unsolved Jigsaw Puzzle of the
Immune Response in Chagas
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Laboratorio de Inmunología de las Infecciones por Tripanosomátidos, Instituto de Investigaciones en Ingeniería Genética y
Biología Molecular (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
Trypanosoma cruzi interacts with the different arms of the innate and adaptive host’s
immune response in a very complex and flowery manner. The history of host-parasite
co-evolution has provided this protozoan with means of resisting, escaping or subverting
the mechanisms of immunity and establishing a chronic infection. Despite many decades
of research on the subject, the infection remains incurable, and the factors that steer
chronic Chagas disease from an asymptomatic state to clinical onset are still unclear.
As the relationship between T. cruzi and the host immune system is intricate, so is the
amount and diversity of scientific knowledge on the matter. Many of the mechanisms of
immunity are fairly well understood, but unveiling the factors that lead each of these to
success or failure, within the coordinated response as a whole, requires further research.
The intention behind this Review is to compile the available information on the different
aspects of the immune response, with an emphasis on those phenomena that have
been studied and confirmed in the human host. For ease of comprehension, it has
been subdivided in sections that cover the main humoral and cell-mediated components
involved therein. However, we also intend to underline that these elements are not
independent, but function intimately and concertedly. Here, we summarize years of
investigation carried out to unravel the puzzling interplay between the host and the
parasite.
Keywords: Trypanosoma cruzi, humoral immunity, cellular immunity, innate immune response, adaptive immune
response, immune evasion, Chagas disease, parasite
INTRODUCTION
More than a century after its discovery, Chagas disease continues to be one of themain public health
problems in South and Central America, with approximate numbers of 6–7 million people infected
in the world, 100million at risk of infection, 56 thousand new cases per year and 12 thousand deaths
per year (1, 2). It is the main parasitic disease in the Western Hemisphere, and its socioeconomic
boundary is 7.5 times greater than that of malaria (3).
The World Health Organization (WHO) includes it in the list of the 20 Neglected Tropical
Diseases. This implies that, along with other clinically diverse infections, Chagas disease is strongly
associated with poverty, flourishing in disadvantaged environments, and persisting especially in
tropical areas, where the diseases of this group tend to coexist. The environments to which vectors
are best adapted and where they thrive are often linked to precarious housing conditions, and this
constitutes an additional nexus between disease and poverty. Likewise, the WHO also points out
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that these diseases “have traditionally ranked low on national
and international health agendas. They cause massive but hidden
and silent suffering, and frequently kill, but not in numbers
comparable to the deaths caused by HIV/AIDS, tuberculosis or
malaria” (4).
It was not until recently that due attention began to be given
to a relatively modern factor that affects the distribution of
Chagas’ disease and expands its borders (5). Despite originally
being limited by the ecology of the vector, human migratory
phenomena from rural areas to urban centers and from endemic
to non-endemic countries have generated new challenges for
the epidemiological control of the disease (1, 3). Economic
stagnation and political repression have stimulated, since the
last two decades of the 20th century, different migratory
waves conferring the disease a character of globalized public
health problem (5). It is estimated that the prevalence of
infection among all Latin American migrants living in Europe
is 4.2%, while approximately 300 thousand immigrants carry the
infection in the USA (3, 6). However, and as aggravating factor,
the underdiagnosis index is estimated to be around 95%, and
health professionals in non-endemic countries lack the necessary
expertise to provide adequate care to the sick (6, 7). Also in
the context of these demographic movements, Chagas disease
interacts reciprocally with socioeconomic factors, such as labor
formality and healthcare access, to deepen the disadvantages of
already disadvantaged social sectors (1).
The routes of transmission and the life cycle of
T. cruzi are illustrated and explained in further detail in
Supplementary Figures 1, 2. When vectorially acquired,
Chagas disease has two major phases. The acute phase lasts
approximately 2 months and typically presents a high number
of parasites circulating in the blood. In most cases symptoms
are subclinical. When clinically observable, they tend to be
unspecific (with the exceptions of unilateral palpebral oedema,
called Romaña sign, and skin lesion known as chagoma) and
usually vanish on their own, within a few weeks or months.
If untreated, patients usually enter in the second phase of the
disease, the chronic phase, which begins asymptomatic, and may
so remain for the rest of their life. However, up to 30-40% of these
patients develop clinical manifestations, being cardiomyopathy,
and megaviscera (enlargement of the esophagus or colon), the
most prevailing (6). Congenital Chagas disease, due to mother-
to-child transmission, renders nowadays approximately 1–5% of
the infected cases. It evolves like the vector-borne infection, with
the same risk of developing clinical manifestations of chronic
Chagas disease later in life, unless treated (8). On the other
hand, orally-transmitted Chagas disease, mainly reported in the
Amazon region, is associated with unusually severe and early
clinical symptoms, and high fatality rates due to high prevalence
of cardiac pathology (9).
Even after years of profuse research aiming at unveiling
the mechanisms involved in the pathogenesis of Chagas
disease, the reason why some patients stay asymptomatic while
others progress to symptomatic aﬄiction remains obscure. Two
hypotheses have been laid on the table: one of them proposes
that tissue damage is a direct consequence of the presence of live
parasites, inducing chronic inflammation, while the other settles
down on a self-reactive response triggered by molecular mimicry
between parasite and host proteins. Certainly, these mechanisms
are not mutually exclusive (10) and they may both contribute to
the clinical outcome of the infection.
Independently of the mechanisms involved in pathology, the
main underlaying actor is the immune response orchestrated by
the host organism, and its interaction with the parasite. In this
context, it is important to keep in mind the broad spectrum of
activation profiles found in Chagas disease patients, which can
be attributed to multiple factors: the infective load, the route
of infection, the genetic background of the parasite (which is
linked to the presence or absence of virulence factors) and of
the host, the influence of neuro-endocrine factors on the adaptive
response, among others (11).
After infection, T. cruzi induces a strong innate and adaptive
immune response in mammals that plays a major role during
the acute and chronic phases of the disease. Nonetheless, this
response is not effective enough to achieve complete clearance of
the parasite. In order to survive within the mammal host, and as a
consequence of an extensive history of co-evolution, T. cruzi has
evolved several sophisticated mechanisms to evade the immune
system action, while not critically affecting its host.
In this review, we revisit the results of research that shed light
on the interplay between T. cruzi and the different components of
the innate and adaptive immune response, with a special focus on
the human infection scenario.We also discuss current knowledge
on the mechanisms of immune evasion that enable the parasite
to persist within its host, and the role of the immune response in
protection and pathogenesis in the context of Chagas disease.
INNATE IMMUNITY
The Complement System in T. cruzi
Infection
The complement system comprises more than 40 plasma
circulating proteins which opsonize pathogens, recruit
phagocytes to the infection site and, in some cases, eliminate
the pathogen in a direct fashion. It functions as a cascade
of proteolytic events that amplifies the signal generated by
the presence of a pathogen to favor its efficient clearance.
The first activation step can occur by three different ways,
known as the classical, alternative and lectin pathways, all of
which converge in the formation of a C3 convertase complex,
and the consequent separation of C3 in C3a and C3b. The
effector mechanisms of the complement depend on this step:
the complement-promoted phagocytosis is mediated by C3b
receptors expressed by neutrophils and macrophages, and C3a
is a pro-inflammatory agent. Furthermore, C3b is necessary for
the generation of the C5 convertase, which gives rise to C5a (a
strong pro-inflammatory signal), and for the formation of pores
on the pathogen’s membrane.
Although all T. cruzi forms are bound by complement factors,
only epimastigotes, as well as metacyclic trypomastigotes of
certain strains, are affected by their effector activities, mainly via
the lectin and alternative pathways (12–14). Escape or subversion
of the effector functions of the complement system ismediated by
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a set of molecules expressed on the parasite surface, which inhibit
or dampen complement activation (Figure 1). Among them,
calreticulin (TcCRT), trypomastigote decay acceleration factor
(T-DAF), T. cruzi complement regulatory protein (TcCRP),
T. cruzi complement C2 receptor inhibitor trispanning (TcCRIT),
and gp58/68 have been studied the most (13, 14).
TcCRT is an endoplasmic reticulum (ER) protein that is
translocated to the parasite surface after infection. It has been
shown to be capable of binding different molecular pattern
sensors, like C1q, mannose binding protein (MBP, also known
as mannose binding lectin) (15) and L-ficolin (16). Therefore,
it affects the first step on the classical and lectin complement
activation pathways. Nevertheless, mannose binding lectin
associated protein (MASP)-2 deficient mice suffer a compromise
of the lectin activation pathway that is only partial, and as a result
no differences with control mice were observed in susceptibility
upon infection in this experimental model (17).
T-DAF is a protein from the inactive trans-sialidase family,
and an analog of human DAF, which modulates the physiological
decay of the alternative and classical pathway C3 convertase. In
order to fulfill its function, both DAFs interfere in the C3bBb
and C4b2a complexes formation, in the classical and alternative
pathways respectively (13, 18, 19).
TcCRP, also known as gp160 (for 160 kDa
glycoprotein) is another inactive trans-sialidase that is a
glycosylphosphatidylinositol (GPI)-anchored to the cell
membrane of the trypomastigote. TcCRP is capable of binding
C3b and C4b, both in their soluble and bound forms, and it
has been shown to interfere in the classical and alternative
complement pathways (20). Furthermore, even though it has not
been empirically tested, its C4 binding capacity could also affect
the lectin pathway (13). Normally, it is not expressed on the
epimastigote and amastigote forms surface, but their exogenous
expression on epimastigotes renders them less susceptible
to complement-mediated lysis (20, 21). Some authors have
proposed a positive correlation between the TcCRP expression
level and the virulence in different T. cruzi strains (22). However,
evidence on that regards is scarce and inconclusive.
TcCRIT is a transmembrane protein homologous to
Schistosoma haematobium ShCRIT (previously known as
trispanning orphan receptor, TOR), and hCRIT in humans.
These proteins have an extracellular acidic domain structurally
similar to the C4 β chain, i.e., its C2 binding site. Hence, TcCRIT
(like its analogs) and C4 compete for the binding of C2, therefore
modulating the C3 convertase formation in the classical pathway
(13, 14).
Trypanosoma cruzi 58/68 glycoprotein (gp58/68) functions
as an analog of endogenous complement regulatory molecules,
diminishing the alternative pathway C3 convertase formation by
inhibiting the union of fB with parasite-bound C3b. Its release
to the environment by trypomastigotes has also been reported,
although the biological relevance of this mechanism is still to be
clarified (13).
In addition to the direct interaction of these proteins with the
complement factors, plasma membrane-derived vesicles [PMVs,
(23)] released by infected host cells or by the parasite itself,
inhibit complement functions (24). In the case of T. cruzi
infection, molecules yet to be identified present in PMVs, impede
C3b deposition on parasite surface, affecting the activity of C3
convertase (24). Even more, Wyllie and Ramirez demonstrated
that PMVs isolated from a certain strain of the parasite can only
confer resistance to complement-mediated lysis to parasites of
their own same strain (25).
Macrophages and Neutrophils
Phagocytes, especially monocytes/macrophages, neutrophils and
dendritic cells (DCs), are the first line of defense against
pathogens on their way through the epithelial barriers.
Monocytes and neutrophils express membrane receptors that
recognize pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs), enabling the
detection and phagocytosis of microorganisms and cellular
debris.
Among these receptors, some of the most relevant in
the recognition of T. cruzi and its components are Toll-
like receptors (TLRs). Up to now, a total of 10 TLRs
have been identified in humans, and 13 in mice (26).
TLR1,−2,−4,−5, and−6 are located on the cell surface,
whereas TLR3,−7,−8, and−9 are expressed in intracellular
compartments (27, 28). GPI-anchors derived from T. cruzi
mucin-like glycoproteins (GPI-mucins) are ligands of TLR2
and−6, while glycoinositolphospholipids (GIPLs) are recognized
by TLR4 (29–31). Furthermore, parasite DNA (which contains
abundant oligodeoxynucleotide unmethylated CpG motifs) and
total RNA have been identified as potent activators of TLR9
and−7, respectively (32, 33). In relation to this, not only
monocyte subsets frequencies but also their expression of
molecules related to PAMPs sensing and antigen presentation
have been reported to be different between chronic Chagas
disease patients and non-infected subjects. This appears to
impact the profile of TH1, TH2, TH17, and Treg cells (the role
of which is discussed later), therefore highlighting the effect of
phagocytes and antigen presentation on the establishment and
profiling of long-term immune memory (34).
One of the principal means by which macrophages and other
phagocytes contribute to the shaping of the response profile
is the secretion of cytokines. In particular, the IL-12 family of
heterodimeric cytokines is mainly produced by macrophages and
DCs, and their signaling pathways polarize the immune response
toward a broad diversity of pro- and anti-inflammatory profiles
(35).With the aid of knock-out murine models, the role of the IL-
12-related cytokines has been explored in experimental T. cruzi
infection, consistently showing the importance of all the different
components evaluated (36–40). However, the results of these
studies are difficult to interpret, given that the knocked-out gene
in each model is most often a component of more than one
cytokine, and these in turn usually have opposite or pleiotropic
effects. Table 1 summarizes the information obtained from these
murine models, and data from experiments with patient samples
that might be linked to observations in mice.
The mechanism by which T. cruzi enters the so called
professional phagocytes has been matter of controversy, since
discordant results have been reported regarding whether it
takes place by means of parasite-extrinsic mechanisms or the
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FIGURE 1 | T. cruzi has mechanisms to inhibit the complement system. The parasite proteins involved in the modulation of the three complement activation pathways
are indicated in black boxes. TcCRT, T. cruzi calreticulin; T-DAF, trypomastigote decay acceleration factor; TcCRP, T. cruzi complement regulatory protein; TcCRIT,
T. cruzi complement C2 receptor inhibitor trispanning.
parasite participates actively in the process. On one hand,
it has been shown that parasite internalization is inhibited
by pharmacological blockade of actin polymerization in the
phagocyte. On the other hand, it has been observed that even
under such conditions the parasite can ingress to macrophages,
supporting the active invasion hypothesis. Current consensus
assumes that at least two different internalization mechanisms
take place during infection: a phagocytic, actin-dependent one,
and another one that relies on microdomain-like cell membrane
structures on the macrophage (43, 44).
Tissue resident macrophages are considered the first host
cells to be invaded by T. cruzi upon infection. Although this
cell type can internalize both trypomastigotes and epimastigotes,
only the former can escape the phagolysosome (18, 44)
(Figure 2). To detoxify the oxidant agents that the activated
macrophage produces for its elimination, the parasite counts on
an antioxidant metabolic network, composed of several enzymes
and non-enzymatic molecules distributed across different sub-
cellular compartments. Amongst them, five peroxidases have
been described: the cytosolic and mitochondrial tryparedoxin
peroxidases (TcCPX and TcMPX, respectively), which detoxify
peroxynitrite, H2O2 and short chain organic hydroperoxides; the
ascorbate-dependent haemoperoxidase (TcAPX), from the ER,
that confers resistance to H2O2; and the glutathione peroxidases
I and II (TcGPXI, located in the glycosome and the cytosol, and
TcGPXII, in the ER), that enable the parasite’s survival to lipid
peroxides and hydroperoxides (18). Additionally, in the murine
infection model, cruzipain, a cysteine-protease from the parasite,
diminishes the macrophage’s trypanocide activity by increasing
the arginase activity, which competes with nitric oxide synthases,
including iNOS, for their substrate, L-arginine (45).
It is worth mentioning that, despite an observed shrinkage
of the morphologically macrophage-like population in flow
cytometry experiments, the analysis of surface molecules
expression demonstrated that monocytes with a pro-
inflammatory phenotype have an increased frequency in
pediatric Chagas disease patients, as compared with non-infected
children of the same age (46).
The interaction between T. cruzi and neutrophils has been
studied in murine model of susceptibility (BALB/c mice)
and resistance (C57BL/6 mice) to infection with Tulahuen
strain parasites (47). In the susceptible model, animals display
increased parasitaemia, number of pseudocysts, and mortality
when monocytes and neutrophils are depleted, as compared
to non-depleted control mice. In contrast, the same depletion
on the resistant model leads to decreased parasitaemia without
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TABLE 1 | Effects of the IL-12 family cytokines in T. cruzi infection.
Knock out murine infection model Affected cytokines/receptors Observed effects Possible correlate with human
data
Mice: IL-12p35−/− (background:
129sv/Ev, backcrossed 5 times with
C57BL/6)
T. cruzi: Tulahuen (37)
IL-12 (p35+p40)
IL-35 (p35+Ebi3)
Reduced IFN-γ, TNF-α, and reactive nitrogen
intermediate species at early infection, later
normalized
No NK and delayed T cell recruitment to the spleen
Increased IL-18 production might partially
compensate the lack of IL-12 by inducing IFN-γ
secretion by spleen cells
IL-12 enhances ex vivo,
T. cruzi-specific proliferative response
from patients PBMC (41)
Mice: IL-12p40−/− (background:
C57BL/6)
T. cruzi: Y (38)
IL-12 (p35+p40)
IL-23 (p19+p40)
Increased parasitaemia and mortality
Impaired IFN-γ and NO production
Higher titer of anti-T. cruzi IgG2b antibodies, similar
titers of other isotype specific antibodies (vs.
wild-type mice)
Mice: Ebi3−/− (background: C57BL/6)
T. cruzi: Tulahuen (36)
IL-27 (p28+Ebi3)
IL-35 (p35+Ebi3)
IL-39 (p19+Ebi3)
Increased parasitaemia and mortality
Increased expression of IL-4, IL-13, and IL-22 in
spleen cells at early infection, later normalized
Increased frequency of CD4+ IFN-γ+and
CD4+ IL-17+ cells in spleen
Increased IL-17A secretion by spleen cells upon ex
vivo restimulation with anti-CD3 antibody at 7 dpi,
normalized at 14 dpi
Increased secretion of IL-4 upon ex vivo
restimulation with anti-CD3 antibody. Improved
survival rate upon in vivo anti-IL-4 treatment
Mice: Ebi3−/− (background: C57BL/6)
T. cruzi: Y (42)
Increased mortality, but lower parasitaemia peak
Increased expression of CCL5, CCR8, and CXCL10
coding mRNA in cardiac tissue, as well as of Th1
related genes
Increased tissue parasitism in heart and liver
Increased IFN-γ production in heart and spleen, and
decreased production of IL-10 in heart
Improved survival rate upon in vivo anti-IFN-γ or
anti-NOS treatment
Mice: WSX-1−/−(background: C57BL/6)
T. cruzi: Tulahuen (39)
IL27Rα (Receptor to IL-27) Increased parasitaemia and mortality Augmented
IL-4 production
Increased levels of IL-27p28 are
related to milder clinical forms of
Chagas disease (42)
Mice: IL-23p19−/−(background:
C57BL/6)
T. cruzi: Tulahuen (40)
IL-23 (p19+p40)
IL39 (p19+Ebi3)
Increased parasitaemia and mortality
Impaired production of IL-17A
changes neither in the number of pseudocysts nor in mortality.
A comparative analysis of the secreted cytokines profile upon
monocytes and neutrophils depletion suggested a protective role
against infection for IL-2, IFN-γ, and TNF-α from macrophages,
while IL-10 secretion seems not to be affected (47). Nonetheless,
in a different study in which BALB/c mice were infected
with Tulahuen strain parasites, neutrophils with a regulatory
phenotype (IL-10 producers) were isolated from the spleen of
T. cruzi-infected animals. In this model, cytokines signaled
via heterodimers comprising the IL-17 receptor A (IL-17RA)
produce opposite effects on parasitaemia upon neutrophil
depletion: while wild type mice exhibit a decrease in this
parameter, animals lacking this receptor component show
increased number of blood-circulating parasites (48). Differences
in the neutrophils induction of nitric oxide (NO) production
on macrophages might explain the differential susceptibility
to infection between BALB/c and C57BL/6 mice. This, in
time, depends on TNF-α and elastase on one hand (a greater
production of these molecules in C57BL/6 mice would have a
protective effect), and prostaglandin E2 and TGF-β on the other
(a greater production of these would lead to susceptibility in
BALB/cmice, as a result of an increased parasite replication) (49).
Nitrogen oxidant species have been demonstrated to be central
to the control of infection in various murine models, mainly
signaled through the IL-12/IFN-γ signaling axis (50, 51), but
also involving TNF-α (51–53), IL-17A (40), and IL-18, the latter
seemingly inducing IFN-γ secretion to compensate for the lack
of IL-12 in a knock-out model (37).
In addition to phagocytosis and pathogen clearance by
neutrophils in the context of the innate immune response, these
cells can also produce fibrous structures made of DNA, histones,
elastase and granular proteins, called neutrophil extracellular
traps (NETs), by a special cell death program known as
netosis. The NETs contribute to pathogen elimination, and their
microbicide activity has been studiedmainly in the neutralization
of bacteria, but their role in the response toward other types
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FIGURE 2 | T. cruzi evades the microbicidal action of the macrophage by escaping from the phagolysosome into the cytoplasm, and by using enzymes that detoxify
oxygen and nitrogen reactive species. The parasite enters the cell and escapes from the normal phagolysosome pathway, before its differentiation, and replication
(Left). On the (Right), the peroxidases used by the parasite to inactivate different components of the oxidative burst imposed by activated macrophage are
represented. TcCPX, T. cruzi cytosolic tryparedoxin peroxidases; TcMPX, T. cruzi mitochondrial tryparedoxin peroxidases; TcAPX, T. cruzi ascorbate-dependent
haemoperoxidase; TcGPXI, T. cruzi glutathione peroxidases I; TcGPXII, T. cruzi glutathione peroxidases II.
of pathogens is not yet clearly understood (54, 55). Sousa-
Rocha et al. demonstrated that trypomastigotes, and soluble
T. cruzi antigens are capable of inducing NETs release on
human neutrophils by activation of TLR2 and−4, and that
this response depends on the activation of the respiratory
burst and the production of reactive oxygen species. These
NETs do not have trypanocide capacity, as they do not affect
parasite viability, but they are able to reduce their infectivity by
inducing trypomastigotes to differentiate into amastigotes in the
extracellular environment (56).
Dendritic Cells
Like macrophages and neutrophils, DCs are also activated in
the presence of PAMPs and DAMPs. Trypanosoma cruzi has
been demonstrated to be internalized by DCs, although murine
model experiments show there are different degrees of infectivity,
associated to parasite strains. This dependence did not show any
relation to Discrete Typing Units (DTUs) (57) nor to biological
parameters of the DC (58).
Experiments with human DCs showed that their function
is affected by factors secreted by the parasite, which induce a
tolerogenic profile by decreasing IL-12 and TNF-α production
(59) (Figure 3). It should be mentioned that under this model,
cytoplasm invasion by the pathogen was observed. Also, a
decrease of class I and II major histocompatibility complex
(MHC) molecules and CD40 co-receptor expression was shown
to be induced on DCs by T. cruzi soluble factors, tampering with
this cell’s antigen presentation capacity (59, 60). These effects
have been attributed, at least partially, to parasite-produced GIPL
(61), and have a direct consequence on T cell activation, as shown
by a decrease in IFN-γ production by these cells in in vitro
antigen presentation experiments, in which DCs were treated
with the parasite prior to their usage as antigen presenting cells
(APC) (60). Experiments with mouse bone marrow-derived DCs
showed that inhibitory receptor SIGLEC-E is activated by the
sialylated ligands on the parasite surface, downregulating IL-12
secretion and upregulating that of IL-10 (62), and may therefore
be involved in immunomodulatory mechanisms associated to
T. cruzi infection. This is in agreement with results by Ersching
et al. who used amurinemodel to demonstrate that DCs that have
been exposed to T. cruzi induce regulatory T (Treg) cells with an
enhanced suppressor capacity on CD8+ T cells (63).
Natural Killer Lymphocytes
Natural killer (NK) cells play a central role in the innate immune
response, especially in infections by intracellular pathogens.
Cytotoxicity directed to the elimination of infected or damaged
cells is one of their main effector mechanisms. Activated NK cells
are also potent producers of IFN-γ, which activates macrophages
and biases naïve T cell differentiation toward a TH1 profile. Both
the cytotoxic and modulatory functions of NK cells are positively
regulated by innate immunity cytokines, mainly IL-12, IL-15, IL-
18, and type I interferons, which enhance cytotoxic capacity and
IFN-γ production. As the role of these cells in T. cruzi infection is
increasingly explored, their relevance has becomemore andmore
obvious (Figure 4).
NK cells’ role on biasing T cell differentiation toward a TH1
profile and activating macrophages via IFN-γ secretion was
demonstrated in the murine T. cruzi infection model. It has
been shown that NK cells produce a peak of IFN-γ secretion
shortly after infection, in a process that is dependent on adherent
cells in the thymus but independent on T cells, and that also
requires the presence of viable parasites (heat- or radiation-killed
parasites failed to activate this cytokine secretion) (64). This IFN-
γ blast may be crucial for the early control of parasitaemia during
the acute phase of the infection. Depleting NK cells from these
mice results in IFN-γ secretion abrogation and IL-10 production
increase, probably causing the immune system to tolerate the
presence of the parasite (64).
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FIGURE 3 | T. cruzi modulates the functionality of dendritic cells, affecting their ability to activate mechanisms of the adaptive immune response. GIPL, T. cruzi
glycosylinositolphospholipids. Blue shaded boxes represent factors and mechanisms considered beneficial for the host.
FIGURE 4 | T. cruzi is a target of NK lymphocytes, which are one of the main
cells of the innate immunity contributing to parasite clearance. However,
T. cruzi also has mechanisms that modulate NK lymphocytes function. Blue
shaded boxes represent factors and mechanisms considered beneficial for the
host.
In addition, NK cells can eliminate extracellular parasites
directly, by means of the quick formation of intercellular contacts
that result in the immediate loss of motility and cell membrane
damage for the parasite, as it was shown inmice. This mechanism
depends on the NK cell activation by IL-12, and involves the
exocytosis of cytotoxic granules, but is perforin-independent
(65, 66), which led to the conclusion that the role of NK cells
in controlling the parasite burden has more to do with direct
extracellular parasite killing than with the elimination of T. cruzi
infected cells.
The observation of a decrease in the infective capacity of the
parasite on cultured mouse fibroblasts in the presence of total
spleen cells, that is reverted when NK cells are depleted, has
been pointed out as evidence for a regulatory role for this cell
subset on non-immune cells in the context of T. cruzi infection.
Looking into this phenomenon, Lieke et al. (67) corroborated
that it is mediated by IFN-γ secretion from NK cells, which
induces an increase in iNOS expression in the fibroblasts. Also,
type I interferons were identified as messengers in this cross-
talk between NK cells and fibroblasts, being produced by both
cell types in response to the parasite. However, the effect of these
interferons and IL-12 on the trypanocide mechanism induced by
NK cells on fibroblast was demonstrated to be neglectable (67).
NK cells are also involved in the maturation of DCs: in
normal physiological conditions, activated NK cells direct DC
maturation by secreting cytokines while suppressing those DCs
that do not undergo full, correct maturation. On that regards,
murine model experiments have shown that live parasites, unlike
their lysate, affect NK cells cytotoxicity on immature DCs,
and that this effect causes greater parasitaemia and lower mice
survival, without affecting parasite burden (66).
In the context of human infection, Ferreira et al. (68)
conducted a microarray-based transcriptomic signature study
on peripheral blood cells from Chagas disease patients, in
which ex vivo transcriptional profiles were compared between
patients classified in different categories: severe cardiopathy,
mild cardiopathy, asymptomatic with negative PCR for T. cruzi
DNA, asymptomatic with positive PCR, and control non-infected
subjects. The expression of genes related to NK cells activity was
found to be upregulated in positive PCR asymptomatic patients
and mild cardiopathy patients, and downregulated in patients
with severe cardiopathy (68).
A phenotypic study of the cell subsets circulating in peripheral
blood from pediatric and adult Chagas disease patients, with
and without cardiac symptoms, suggested a role for pre-NK cells
in the activation of macrophage effector mechanisms, during
early stages of the asymptomatic phase. These pre-NK cells are
predominantly cytokine secretors, in contrast to mature NK
cells which are predominantly cytotoxic. A greater frequency of
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mature NK cells was also observed in asymptomatic patients,
as compared to cardiac patients, suggesting a contribution
of this cell subset to the establishment and/or maintenance
of the lack of symptoms during chronic infection (46).
Additionally, peripheral and cord blood experimental infection
assays highlighted NK cells as the most potent IFN-γ producing
subset, besides also secreting IL-15 (69) in response to the
pathogen, suggesting their relevance in the primary response to
infection.
ADAPTIVE IMMUNITY
B Lymphocytes
B cells are known to play an important role in humoral
adaptive immune responses by producing and secreting
antibodies. However, they also have relevance in cytokine
secretion and antigen presentation to other immune cells,
therefore being a nexus between innate and adaptive immune
responses. Moreover, in recent years, an increasing amount of
studies identify B cell subsets with regulatory functions (70),
suggesting that its purposes are much broader than previously
thought.
B cells and antibodies were amongst the first components of
immunity to be studied in the context of Chagas disease, and as
of today several aspects of their multiple roles remain obscure
(Figure 5). The specificity of antibodies generated upon infection
were the major focus of interest in the early days of this field.
Up to now, the immune epitopes database (IEDB, http://www.
iedb.org) has 89 T. cruzi molecule entries (plus several entries
marked as “other T. cruzi protein”), which contain in total over 2
× 103 epitopes bound by specific antibodies in human infection
and in animal models. Some of these antibodies are often
referred to as “lytic,” meaning they enable complement-mediated
parasite lysis. Amongst target antigens to these antibodies are
gp190, T-DAF, the 90 kDa surface protein and several GPI-
anchored mucin-like glycoproteins. The mechanism by which
these antibodies allow direct lysis of the parasites are thought
to be related to the blockade of the complement evasion
pathways discussed previously (71). Other proteins recognized
by—non necessarily lytic—antibodies produced in response
to T. cruzi infection are mucins (TcMUC), mucin-associated
surface proteins (MASPs), trans-sialidases, amastigote surface
proteins (ASPs), paraflagellar rod protein (TcPRP), kinetoplastid
membrane protein 11 (KMP-11), glycoprotein gp82, the enzyme
neuraminidase, heat shock protein hsp70, tubulin, ribosomal
proteins, and several others (IEDB, accessed June 2018), besides
carbohydrates like the so-called “gal epitope” (gal α1-3 gal)
(72). It is worth mentioning that the recent application of high
throughput technologies and informatics prediction methods
have dramatically expanded the possibilities of exploring the
repertoire of human antibodies produced against infection by
this complex parasite, and constitute promising tools for the
study of the humoral adaptive immune response in Chagas
disease (73, 74).
The importance of anti-T. cruzi antibodies to the control of
infection has been demonstrated in the mouse infection model:
in spite of living significantly longer than T cell deficient animals,
mutant mice incapable of producing antibodies (muMT−/−) are
unable to control parasitic growth and succumb to infection
during the acute phase (75).
Despite this, antibodies produced against T. cruzi do not
effectively eliminate the parasite, providing an opportunity to
establish a persistent infection. This deficient antibody response
is possibly due to three main factors. The first is antigenic
variability: the parasite exposes a variety of antigens on its
surface, such as mucins, trans-sialidases and MASPs, encoded
by highly polymorphic multigenic families. This high diversity
of molecules expressed at the same time delays the activation
of specific B cell clones, and therefore also the production and
maturation of high-affinity antibodies with neutralizing capacity
(18, 76, 77).
The second factor is the reduction of immature B cells in the
bone marrow (BM), probably as a consequence of an increased
apoptosis rate. It was proposed that, by affecting the BM,
T. cruzi could compromise the whole humoral immune response,
limiting the generation of mature B cells in the periphery (78, 79).
The third factor is non-specific polyclonal B cell activation:
some parasite molecules have been demonstrated to cause non-
specific, T-independent activation and proliferation of B cells
in murine models of infection, generating splenomegaly and
hypergammaglobulinemia associated to the production of non-
T. cruzi-specific antibodies (18, 80–82). This phenomenon has
been linked to susceptibility to infection in BALB/c mice in
contrast with resistance in C57BL/6 mice. Monitoring total
and anti-T. cruzi (measured as TcCRP-specific antibodies) IgM
and IgG production, it was shown that while BALB/c mice do
not produce IgM in response to the parasite, they suffer from
hypergammaglobulinaemia and low parasite-specific response,
and that C57BL/6 exhibit an initial increase in total IgG and IgM
followed by a rise in anti-CRP antibody titer of both isotypes (83).
A case of accidental infection permitted the observation of this
phenomenon in the context of human acute infection, exhibiting
expansion of total antibodies, initially IgM and IgA, followed
by IgG with specificities not related to T. cruzi antigens (84).
Glutamate dehydrogenase (TcGDH) (85), proline racemase (86),
and TcTS (87) are amongst the parasitic proteins identified as
polyclonal B cell mitogens. This polyclonal B cell activation may
be functional to an early host defense with antibodies against a
big spectrum of conserved structures present inT. cruzi and other
pathogens, allowing the clearance of the parasite. Nonetheless, it
might also be exploited by the parasite to avoid the host specific
immune response: promoting a generalized expansion of the
B cell subset, regardless of their specificity, would result in a
diminished frequency of pathogen-specific antibody-producing
B cells (79).
At this point, it is worth mentioning that one of the most
widespread hypotheses explaining the pathogenesis of Chagas
disease is the existence of self-reactive immune mechanisms
developed as a consequence of infection (88). In particular,
evidence of molecular mimicry has been found between host
and parasite molecules, and it has been suggested that this
may lead to the production of self-reactive antibodies with
deleterious effects. Examples of this are T. cruzi peptide
B13 and human myosin heavy chain, ribosomal P proteins
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FIGURE 5 | B cell-mediated response is central to the control of T. cruzi infection, but is also affected by parasite mechanisms that favor its escape and are
associated with pathogenesis. The beneficial factors for the host are highlighted in blue shaded boxes, while the factors considered harmful to the host are shown in
red shaded boxes. T-DAF, trypomastigote decay acceleration factor; TcTs, T. cruzi Transialidase; TcGDH, T. cruzi Glutamate dehydrogenase.
and muscarinic and adrenergic receptors, and protein FL-
160 and a neuronal 47 kDa protein, among others (89–
92).
Given that self-reactivity has been observedmost frequently in
the chronic phase of Chagas disease in humans and experimental
models, some authors propose that it is a result of a low level
stimulation of self-reactive cells during a long period of time (93).
However, cellular and humoral self-reactivity against myosin,
and antibodies against actin and tubulin have been found in
acutely infected mice (93, 94) and anti-laminin antibodies were
detected in acutely infected humans (84), suggesting that this
phenomenon may actually be initiated earlier, during the acute
phase of infection.
B cell-deficient (muMT−/− C57BL/6) mice have been used
in experimental models of acute infection to test the relevance
of these cells’ contribution to anti-T. cruzi response. A deficient
expansion of CD4+ and CD8+ T cells was observed in the
absence of mature B cells, in particular within the memory
T cell subsets, along with diminished TH1, TH17, and Treg
populations. This suggests that B cells are crucial for the
establishment of T. cruzi-specific memory T cell populations
which, as it is discussed later, are essential for controlling the
infection. In the absence of mature B cells, the frequency of IFN-
γ+CD4+ T cells decreases, while that of TNF+CD4+ T cells
rises with concomitant higher plasma levels of this cytokine. In
addition, the frequency of CD4+ T cells expressing inhibitory
receptors is lower than in wild type infected mice, which
may imply hampered regulation of these populations. All of
these contribute to an overall exacerbated, unconventional and
deleterious pro-inflammatory state (95, 96). Experiments in a
murine model of vaccination with a TcTS peptide confirmed
some of these observations, and added that even though B cells
are indispensable for the systemic adaptive response generated by
this vaccine, they would not be necessary for the vaccine-induced
response in the mucosa (although experimentally observed in the
spleen) (97).
An unexpected capacity of B cells, first observed in the murine
model of infection with T. cruzi, is that of producing IL-17
to an extent even greater than TH17 cells (which are often
considered as the main source of this cytokine) do (95, 98).
Remarkably, this response seems to be activated by the enzymatic
activity of the parasitic TcTS on the CD45 receptor expressed on
the surface of the B cell, and depends on a signaling pathway
and a transcriptional program different from those that direct
TH17 cells activation (98). These authors also demonstrated that
human tonsillar B cells, obtained from non-infected donors,
secrete IL-17 when co-cultured with T. cruzi trypomastigotes. In
this set-up, anti-TcTS antibodies blocked this activation pathway
(98). This is in agreement with a previous observation by
Magalhaes et al. who pointed out that a large proportion of
the IL-17+ lymphocytes found in peripheral blood from Chagas
disease patients are CD4− and CD8− (99). Altogether, these
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results highlight the role of B cells in the modulation and profile
definition of the T cell response.
The frequency of blood-circulating B cells and particular
B cell subsets is also linked to immunity and homeostasis,
and is often affected by infectious processes. An increase in
the frequency of circulating B cell seems to occur during the
late acute phase of T. cruzi infection in humans, but only
becoming significant at the beginning of the chronic phase
(100). Nonetheless, it has been proposed that, in patients with
established chronic Chagas disease, the number of CD19+ cells
is not different from that of non-infected individuals (101,
102), suggesting a subsequent contraction of this population.
Despite this apparent unaltered number of circulating B cells,
the same is not true about the representation of the different
B cell subsets: Fernández et al. reported a selective decrease
in B cells from the memory subset (CD19+CD27+IgD−) with
different degrees of differentiation (both IgM+ and IgG+), and in
terminally differentiated plasma cells (CD19+CD27+CD138+),
along with an increase in the unconventional double negative
B cells (CD19+CD27−IgD−IgG+) (102). This implies, as the
authors discuss, an increase in B cells incapable of generating
a substantial anti-T. cruzi IgG antibody response. In addition,
Fares et al. (101) found an augmented CD21-expressing B cell
population, CD21 being a CD19-associated co-receptor which
enhances the activation signals generated by membrane Ig in
contact with complement-bound antigen and T cell-dependent
response antigens (103).
Unlike the conventional (B2) cells, the B1 cell subset
produces and secretes polyreactive natural antibodies and
immunomodulatory molecules, which play an important role in
protection against certain infections (104, 105). In mice, they
constitute only aminor fraction of the B cells in spleen and lymph
nodes, but they are the most abundant in the peritoneal and
pleural environments (106). Infected BALB Xid mice carrying a
mutation that prevents B1 cell development showed poor B cell
response to T. cruzi infection and low levels of specific and non-
specific antibodies in serum. However, they were able to control
parasitaemia and developed almost no pathology in the early
chronic phase of the disease (107). The resistance of these mice
to experimental infection was attributed to the absence of IL-10
secreting B1 cells and high levels of IFN-γ (108). In this sense,
Merino et al. (109), showed a decrease in peritoneal CD19+ cells
in T cruzi-infected mice, with different kinetics for the B1 and B2
subsets. This was associated with an enhanced differentiation into
plasma cells. Furthermore, atypical plasma cells called “Mott-
like cells” were detected in the peritoneum of infected mice,
containing high numbers of Ig+ cytoplasmic granules. Although
the specific role of these cells in T. cruzi infection has not been
clarified yet, the authors suggest that they might be associated
with self-reactive responses observed in Chagas disease. Based
on these results, it has been suggested that B1 cells would play a
detrimental rather than protective role in Chagas disease (110).
On the other hand, and as it was mentioned before, B1 cells
may help to control the infection during the acute phase, by
releasing high amounts of non-specific IgM and IgG, which
rapidly decrease parasitaemia (109). Nevertheless, their precise
role in the context of human infection is yet to be clarified.
Finally, regulatory B cells (Breg) secrete IL-10, IL-35, and
TGF-β, and suppress autoimmune pathologies by hampering
the expansion of pathogenic T cell clones and other pro-
inflammatory lymphocytes, and promoting regulatory T cells
(Tregs) differentiation (70, 111, 112). Fares et al. described that
patients with chronic Chagas disease have an increased frequency
of IL-10 and TGF-β producing B cells in peripheral blood, both
in basal state and upon in vitro stimulation with parasite lysate
(101). It is yet to be determined whether, in the context of chronic
Chagas disease, these cells have a benign effect by containing
an overly inflammatory response, or detrimental by favoring
tolerance toward the parasite presence.
T Lymphocytes
T cell response is initiated upon signals produced by the
recognition of peptide-MHC complexes on the surface of APC
by the T cell receptor (TCR). The ultimate consequence of
this activation is the generation of a large number of effector,
pathogen-specific T cells (TE), departing from a relatively small
set of naïve T cells (TN) with diverse specificity. In the context
of an acute infection, T cell response can be dissected in
three phases: (i) priming and expansion, (ii) resolution and
contraction, and (iii) memory (113).
During the first phase, T cells divide and differentiate into
TE cells, increasing their expression of CD69 (which results
in augmented retention in lymphoid tissues), CD25 (IL-2Rα),
CD40L (which enables induction of macrophages maturation
and B cell helping functions), and CTLA-4 (an inhibitory
receptor that modulates the response). Simultaneously, activated
T cells increase other adhesion molecules and chemokine
receptors that favor migration to and retention in lymphoid
organs. Activated T cells may produce only one cytokine
(monofunctional T cells), or simultaneously produce multiple
cytokines (polyfunctional T cells). In general, polyfunctionality
is considered a correlate of protection in the context of
infection (114) and vaccination (115). Altogether, the changes
that the T cell undergoes upon activation promote rapid
amplification of specific response, generation of effector and
memory populations, enhancement of APC functions, and
circumvention of the response within non-pathological levels.
In the case of chronic Chagas disease, it has been shown that
patients have an increased frequency of circulating activated T
cells, and that these cells secrete pro- and anti-inflammatory
cytokines (116). However, T cell proliferative response is
hampered in Chagas disease patients, at least in vitro, upon
exposure to a strong, non-specific mitogen, and decreased
expression of receptors involved in T cell activation is observed.
Furthermore, proliferation of T cells from non-infected donors
is inhibited in the presence of T. cruzi antigens (117, 118).
T cell response is particularly important for the maintenance
of the typically low parasitaemia in the chronic phase of the
disease (119), and if impaired (e.g., in VIH co-infection cases),
it leads to rapid clinical onset (120, 121). However, exacerbated
inflammation may lead to pathology and its regulation is key
to controlling tissue damage and disease progression (6). T cells
are central to this point since, as we discuss later, they have
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been linked to both the generation and the regulation of tissue
inflammatory processes in the context of Chagas disease.
After the elimination of the antigen source, although this is not
exactly the case in chronic infections, clonal contraction, takes
place. The dominant process in this phase is death by apoptosis
of the vast majority of the activated TE cells, which allows
the immune system to go back to its homeostatic state (122).
Nevertheless, the activation of TN cells gives rise not only to the
great expansion of an effector population of selected specificity,
but also to the differentiation of memory T cells (TM) that remain
beyond the contraction phase. These have a remarkable capacity
to self-renew by proliferation and perpetuate in the long term,
and are specially efficient in acquiring effector functions rapidly
upon a new event of activation (113). Within this population,
two major subsets can be distinguished: central memory T cells
(TCM) home at the lymph nodes, have a low effector capacity
but high sensibility to stimulation and proliferation capability
upon stimulation, specialize in long term immune protection;
and effector memory T cells (TEM), homing at peripheral tissue,
which can rapidly produce effector profile cytokines, but have a
limited proliferative capacity (123, 124). On that regards, Fiuza et
al. have reported that chronic Chagas patients have an increased
frequency of circulating TCM cells as compared to non-infected
individuals, regardless of their clinical status (125), which might
be attributed to a state of chronic activation.
In circumstances of persistent antigenic exposition, memory
T cells may undergo a process termed exhaustion, characterized
by the hierarchical loss of effector functions, altered expression
and usage of transcription factors, metabolic disarrangements,
and increased and sustained expression of inhibitory receptors
(126, 127). Under normal physiological conditions, the latter take
part in the control of inflammation and the contraction of TE
cell populations after antigen source elimination. These events
are required for the uprising of functional T cell memory, and
therefore, the conditions that lead to exhaustion result in the
failure of a normal acquisition of a homeostatic memory T cell
response (126).
In the murine chronic T. cruzi infection model, lack of
cytokine production was observed in T cells recovered from
tissue infiltrates, suggesting some degree of dysfunctionality
(128). Despite some authors claim that the picture observed
in this model does not fully fit the description of a T cell
exhaustion process (121, 129), studies carried on chronic Chagas
disease patients samples revealed the presence of exhausted T
cells, exhibiting a direct relationship between their frequency and
the severity of the cardiac disease (130, 131). Furthermore, an
association between therapeutic success of benznidazole (one of
the two anti-parasitic drugs of approved use for the treatment
of acute Chagas disease) in pediatric patients, and the loss of
parasite-specific IFN-γ producing T cells was observed (132).
Also, the treatment of chronic patients seems to restore T
cell populations functionality and composition, in terms of
state of activation and differentiation (132, 133). This evidence
supports the relevance of persistent antigenic stimulation during
chronic T. cruzi infection in the development of an inefficient
T cell response in the long term. In line with this, patients
with discordant serological tests exhibit a broader, more diverse
cellular activation profile against T. cruzi antigens than that
of chronic Chagas disease patients with consistently positive
serology. Hence, serodiscordant patients may be regarded as
individuals whowere once, transiently infected, but who achieved
T cell-mediated clearance of the parasite, and as a consequence
their humoral anti-T. cruzi response is circumscribed to basal,
“resting memory” levels (134).
Having established this general framework of available
knowledge on T cell response to infection, and in order
to facilitate their comprehension, the particulars of T. cruzi
interactions with CD4+ and CD8+ T cells are approached
separately, in the next subsections, and they are summarized in
Figures 6, 7.
Cytotoxic T Lymphocytes and Elimination of the
Intracellular Forms of T. cruzi
Activation of CD8+ T cells implies antigen recognition by the
TCR in the context of a class I MHC molecule, and second
signals provided by the APC, or by other lymphocytes, especially
TH cells. The latter are particularly relevant in situations in
which antigen presentation is not very efficient and the innate
response to the pathogen is relatively weak, which is the case
of latent infections (135, 136). The result of this activation is
the acquisition by the CD8+ T cell of the molecular machinery
required for the elimination of the target cell, a process
that constitutes the signature of CTL differentiation (137).
Specifically, cytoplasmic granules containing proteins such as
perforin and granzymes are developed, and these will later allow
the CTL to eliminate other cells (138). Additionally, cytokine
production, mainly IFN-γ, is triggered (135).
Given that the replicative phase of T. cruzi’s life cycle within
the human host takes place in the intracellular environment, CTL
response has been, within the last few decades, the predominant
subject in the study of T cell response in the context of Chagas
disease (Figure 6). It has been demonstrated that CD8+ T cells
are an essential agent in the control of T. cruzi infection (29),
as proven in murine models with depletion (139) or genetic
deletion of this subset (140), in which animals do not survive
the acute phase of the infection. It is also known that IFN-γ
secretion is critical for the protective function of CD8+ T cells
(29), and that one of the mechanisms by which this cytokine
mediates protection is NO production (50, 53). Nonetheless, it
would not be the only mechanism, since IFN-γ knock-out mice
exhibit a different phenotype than iNOS knock-out mice, the
former presenting a more severe onset and resembling that of
CD4+ and CD8+ double-deficient mutants (141, 142). TNF-α
has also been proven to be secreted by T. cruzi-specific CD8+
T cells isolated from Chagas disease patients (143). In addition, a
reduction in the frequency of circulating CD8+ T cells in severe
cardiac patients was observed in comparison with asymptomatic
and mild cardiac patients, suggesting that CTL response might
have a role in preventing the progression of the cardiac symptoms
(144).
Despite the aforementioned, and given the experimental
and clinical evidence, the deployment of a T. cruzi specific
CD8+ T cell response does not imply protection against
infection/reinfection. Diverse lines of research have tried to
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FIGURE 6 | CD8+ T lymphocytes play a fundamental role in the control of parasitaemia and the elimination of cells infected with T. cruzi, but their chronic stimulation
impairs their function. In addition, CD8+ T cells are involved in the pathogenic inflammatory processes of Chagas disease. The beneficial factors for the host are
highlighted in blue shaded boxes, while the factors considered harmful to the host are shown in red shaded boxes. ASP, amastigote surface proteins; TcTs, T. cruzi
transialidase; TcPRP, T. cruzi paraflagellar rod protein; KMP11, kinetoplastid membrane protein 11; TSA-1, trypomastigote surface antigen-1.
clarify the reason for which the established immune memory is
uncapable of mounting an effective CTL response toward the
parasite. One particular feature of this system, probably common
to other parasites with an intracellular replicative phase, is that
expansion and contraction of CD8+ T cells (experimentally
assessed as cytotoxic activity and IFN-γ producing cells
frequency of T cells against a TcTS and an ASP-2 epitopes in
mice) occur with a certain delay in response to acute infection,
as compared to the usual timings observed in responses toward
viruses and intracellular bacteria (145). A likely explanation
for this is that the initial infection goes unnoticed by the
immune system, and therefore an effective activation of the
innate response is withheld until the first round of replication and
reinfection, which takes place 4–5 days afterwards (145–147).
Stem cell-like memory T cells (TSCM), a recently described
subset, seem to be the primary reservoir of specific memory
T cells, and to permanently replenish TCM populations by
proliferation and differentiation (124, 148–150). The persistent
antigenic stimulus posed by chronic T. cruzi infection takes its
toll on the maintenance of a functional memory population:
it has been observed that patients with chronic Chagas disease
have an imbalanced composition of the CD8+ memory T
cell subset, with a lower frequency of TSCM cells associated
with a higher frequency of TTE cells, as compared to non-
infected subjects (151). Accordingly, a different study reports a
higher frequency of CD8+CD45RA+IFN-γ+ T cells in cardiac
Chagas disease patients, compared to that of asymptomatic
Chagas patients and non-infected individuals (125). Although the
authors of this article propose that this phenotype denotes that
they are naïve CD8+ T cells, they might as well be terminally
differentiated CD8+ T cells (152), which would further support
the hypothesis of a progressive exhaustion of the CTL response
associated to cardiac function compromise. In agreement with
this, monofunctional CD8+ T cells have an increased frequency
upon in vitro stimulation with parasite lysate in patients with
severe cardiomyopathy, as compared to patients with milder
forms of the disease (151). Additionally, a reduction of the
TEM subset in favor of an augmented terminal effector (TTE)
subset within circulating CD8+ T cells has been demonstrated
to occur in cardiac Chagas disease patients, which suggests that
CTL-mediated protection against cardiac progression depends
on the existence of an elevated number of competent CD8+
memory T cells, i.e., in non-terminal states of differentiation
(144, 153). Also, an augmented expression of CTLA-4 on
the surface of CD8+ T cells was observed in asymptomatic
patients. Even though this was not the case for cardiac patients,
an increment in the frequency of CD8+ T cells positive for
intracellular CTLA-4 was detected (154). In partial discordance,
an ulterior study showed a significantly increased frequency of
CTLA-4 expressing CD8+ T cells in Chagas disease patients,
with and without cardiac symptoms (155). Polymorphisms
in the sequence of this receptor which affect its expression
level may have an influence on the clinical outcome of the
infection (156).
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FIGURE 7 | CD4+ T lymphocytes activate, enhance or modulate mechanisms of the immune response against T. cruzi infection. The control of the disease requires a
balanced response in which there is a compromise between the activation of microbicidal functions and the control of inflammatory damage. The beneficial factors for
the host are highlighted in blue shaded boxes, while the factors considered harmful to the host are shown in red shaded boxes. KMP11, kinetoplastid membrane
protein 11; TcMUC, T. cruzi mucins.
Another component of this dysfunctional response panorama
is a deficient CD28-IL-2 signaling axis. Since IL-2 is required
for the survival of an activated T cell and the generation and
maintenance of T cell memory, a reduced secretion of this
cytokine is likely to lead not only to a diminished effector
response, but also to physical deletion of specific activated T cell
clones (144, 157).
Regarding the specificity of CD8+ T cell response, several
epitopes have been described, being those derived from proteins
within the trans-sialidase proteins family the most thoroughly
studied. In particular, TSKb20, a peptide predicted to bindmouse
MHC class I molecule H-2Kb, has demonstrated a high level of
immunodominance in the murine infection model, with specific
cells reaching up to 30% of the circulating CD8+ T lymphocytes
(158, 159). This CD8+ T cell response, highly focused in a few
epitopes, was proposed as a mechanism for the parasite to evade
the immune response (159). However, it was later demonstrated
that inducing tolerance toward the TSKb20 epitope has a
negative effect on the control of parasitaemia in the murine
model, which rules out the hypothesis of immunodominance
contributing to parasite escape by impairment of a broader
response (146). Furthermore, even though the observation of
TcTS immunodominant epitopes is often extrapolated to T. cruzi
infection in general, there is not sufficient evidence of a correlate
in the context of human infection. A predictive approach similar
to the one which led to the TSKb20 epitope was applied to the
HLA-A2 supertype of human class I MHC alleles, pointing out
similar trans-sialidase epitopes, which induced diverse levels of
reactivity in IFN-γ ELISPOT experiments with HLA-A∗02:01+
chronic Chagas patients samples (158).
The family of trans-sialidases and related proteins has
caught the interest of many researchers from the field of
T cell immunology of Chagas disease. In addition to their
aforementioned role in escape and immunomodulation, and the
existence of T cell epitopes derived from these proteins, they
constitute an extremely diverse set of molecules, with about
1,400 different proteins annotated on the genome of T. cruzi (CL
Brener strain), and an estimate of 1,800 unannotated variants.
Conversely, Leishmania species lack this family of proteins, and
in T. brucei it only has 6 members, which suggests this group
of proteins was extraordinarily expanded when T. cruzi diverged
from the other trypanosomatids (146). From an evolutive point
of view, it is tempting to speculate on the relevance of this
phenomenon for the success of T. cruzi as a parasitic organism,
and it might therefore have a relevance for the immune response
toward infection.
Other CD8+ T cell epitopes from T. cruzi trans-sialidase
family proteins, confirmed as immunogens in HLA-A∗02:01+
patients, are the trypomastigote surface antigen (TSA)-1-
derived peptide 77.2 (160), amastigote surface proteins (ASP)-
1 and−2 (161), paraflagellar rod proteins (TcPRP)-2 and−3
(162), cruzipain, and FL-160 (163). Kinetoplastid membrane
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protein (KMP)-11, is a non-trans-sialidase CD8+ T cell epitopes-
containing protein, demonstrated to be recognized by cells
from chronic Chagas patients. Other proteins that activate
murine CD8+ T cells, but without confirmed immunogenicity
in humans, are LYT-1, β-adaptin, paraflagellar Ca+2 binding
protein (CaBP) and heat shock protein (HSP) (141, 164).
It is worth mentioning that, regardless of their specificity,
an expansion of TCR-Vβ 3.1-expressing T cells was observed
within the CD8+CD28+ subset in Chagas disease patients (165),
suggesting a preferential activation of T cells expressing this TCR
family in the context of T. cruzi chronic infection.
Several pieces of research have aimed at determining the
frequency and phenotype of T. cruzi-specific CD8+ T cells
utilizing parasite epitopes (TSA-1, ASP-1 and−2, CaBP, LYT-
1) in ELISA-, ELISPOT- and intracellular cytokine staining
(ICS)-based approaches. The success of these strategies has been
strongly hampered by the low frequency of such cells in the
circulation of chronic Chagas patients (130, 141, 158). This low
frequency was shown to be exclusive for the T. cruzi-specific
cells, by comparison with the response toward an influenza virus
peptide in samples from the same subjects. Consistent evidence
had already been obtained in the murine model, infecting mice
with transgenic parasites expressing the heterologous antigen
OVA, in secretory or GPI-anchored versions. Results indicated
an initial expansion of OVA-specific CD8+ T cells, but these were
only maintained in low frequencies (166). Different explanations
were proposed for this feature. One of them involves the diversity
of peptides incorporated to the class I MHC antigen processing
and presenting machinery: if too many different epitopes are
shown on the surface of an APC, it is possible that they will
compete for antigen presentation and that in consequence none
will reach a density higher than the threshold necessary for T
cell activation. Another hypothesis relates it to the loss of effector
function and peripheral tissue suppression (130, 141).
Besides its participation, with the mentioned nuances, in the
elimination of the parasite during infection, a remarkable amount
of evidence suggests that CD8+ T cells are also involved in
tissue damage and inflammatory processes linked to the clinical
manifestations of Chagas disease (167–169). Inflammatory
infiltrates in patients with cardiac or digestive forms of the
disease are rich in activated CD8+ T cells, and these express
cytolytic molecules like granzymes and TIA-1 (116, 170, 171).
A predominance of pro-inflammatory cytokines-producing cells
in cardiac patients was also reported (172), although cytokine
profile comparative studies between asymptomatic and cardiac
Chagas disease patients showed discordant results: some authors
state that IFN-γ secretion has a protective effect regarding the
development of the symptoms (121, 130, 173), while others put
forwards a harmful effect for this pro-inflammatory cytokine
on cardiac function (173–175). A relationship between the TTE
enriched CD8+ T cells profile in cardiac patients and the
cardiac damage itself has been proposed, given the enhanced
cytotoxic capacity of this subset (151). The accumulated
evidence on that regards highlights the importance of the
regulation of the response in order to achieve a balance between
an efficient effector activity and controlling inflammatory
damage.
Interestingly, a recent study demonstrates that CTL have
a direct trypanocide action on intracellular and circulating
parasites (176). Results showed that, although it is not necessary
for the elimination of infected host cells via perforin and
granzyme B, granulysin is required for the intracellular parasites
viability to be affected. Authors propose that granzymes enter the
infected cells through the action of perforin, and from thereon
penetrate amastigotes by means of granulysin. In regard to the
circulating trypomastigotes, it has been proven that they can
only be affected by granzyme B in the presence of granulysin.
Notably, rodents lack this protein, which puts in evidence certain
limitations of the classicalmurinemodel of infection for the study
of CTL response in Chagas disease. This study also demonstrated
that genetically engineered mice which express the enzyme have
a better control of the infection and of the cardiac tissue damage,
resulting in better survival rates (176).
Helper T Cells and Specific Immune Response
Modulation
CD4+ T cells are characterized by the expression of surface
molecules and the secretion of cytokines which modulate the
activity of other cells, mainly macrophages, DCs and other
lymphocytes. Upon activation, they stimulate, via CD40L, DCs
that had encountered pathogens, promoting their maturation
and the production of polarizing chemokines and cytokines. This
is critical for the induction of an appropriate CTL response.
Some activated CD4+ T cells increase CXCR5 expression, which
directs their migration toward the B cell follicles in lymphoid
organs, where they interact with B cells and differentiate into
follicular helper T cells (TFH), specialized in favoring the selection
of specific B cells and inducing them to produce high affinity
antibody production. The vast majority of proliferating activated
CD4+ T cells differentiate into one of multiple TH profiles,
acquiring different migratory behavior and effector properties,
and they enter circulation to extravasate into inflamed peripheral
tissue. Once there and upon antigen recognition, they produce
cytokines according to their TH profile, in order to potentiate
the activity of other immune system cells present in situ. The
diversity of TH phenotypes generated during primary response to
an infection is important, since it will be mirrored by the diversity
of memory T cells that will persist beyond infection (177).
It is known that in the chronic T. cruzi infection murine
model, CD4+ T cells are a main component of the cardiac lesions
infiltrates, which might suggest they are relevant to the response
against the parasite (178). Nonetheless, and possibly due to the
indirect nature of their physiologic role, i.e., their ultimate effect
requires collaboration with other cells, little is known about their
involvement in Chagas disease, especially in comparison with
the extension to which CD8+ T cell response has been studied
(Figure 7). A class II MHC knock-out mouse model applied
to the study of the CD4+/CD8+ T cell collaboration led to
the conclusion that CD4+ T cells are not absolutely necessary
for the establishment of a CTL response (179). However, the
specificity profile and migratory patterns of the expanded CD8+
T cells were not the same as those in wild type control mice, and
transgenic animals presented a substantially higher susceptibility
to infection, perishing to it in relatively short timespans (179).
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This not only limits the utility of this model for the evaluation
of the role TH cells play in the chronic T. cruzi infection
scenario, but also demonstrates that, despite not essential for
the generation and expansion of parasite-specific CD8+ T cells,
CD4+ are indeed important for the control of infection and/or
inflammation.
The variety of different TH cell profiles, defined according
to the cytokines they produce and the expression of typical
transcription factors, is tightly linked to their function, since
the predominance of one or other profile in the context of a
response depends on the nature of the pathogen, and therefore
enables the activation of the mechanisms most convenient for its
elimination (177, 180). Results from the murine model suggest
that, with regards to the level of protection that one or the other
profile against T. cruzi infection, a coordinated response between
TH1 and TH2 profiles is desirable (181, 182), with predominance,
according to several authors, of TH1 effector mechanisms for the
control/elimination of the parasite (183–185).
The mouse infection model has allowed the discovery of some
parasite enzymes that affect the physiology of CD4+ T cells in
diverse ways, constituting potential evasion mechanisms: two
enzymes from the trans-sialidase family (a proper trans-sialidase
and another one lacking this activity), inhibit their expansion
and promote a TH2 cytokine profile, as authors observing a
decrease in the secretion of IFN-γ and an increase in that of
IL-4 suggest. Accordingly, a decreased expression of IL-2 and
its receptor IL-2Rα (CD25), along with a reduction in TCR
signaling, were observed, and IL-10 was demonstrated to be
required for this to occur. Since the trans-sialidase activity
seems not to contribute to this modulation, the authors propose
that a lectin-surface glycoprotein binding-like mechanism is the
cause of these effects (186). Similarly, TcMuc, a sialoglycoprotein
on the surface of T. cruzi, was shown to produce similar
effects on the expression of IL-2 and CD25, and therefore on
the proliferation of murine CD4+ T cells, although cytokine
secretion was more broadly affected in this case, involving not
only IFN-γ, but IL-4, IL-10, and TGF-β as well (187). Here,
the operating mechanism seems to be SIGLEC-E binding (as
it was described for DCs), which is supported by the decrease
in these effects when TcMuc is artificially desialylated (187).
Another molecule modulating the function of these T cells is
KMP-11, which diminishes IFN-γ secretion upon activation,
without modifying that of IL-4 (188). All four agents mentioned,
the active and inactive trans-sialidases, TcMuc and KMP-11,
affect the whole population of CD4+ T cells, regardless of their
specificity (186–188).
In the human infection, Albareda et al. (189) demonstrated
an association of a lower frequency of T. cruzi-specific IFN-
γ producing CD4+ T cells with the degree of severity in
patients with Chagas chronic cardiopathy. The results on this
report also suggest that most parasite-specific circulating CD4+
T cells in patients are newly-recruited cells, and they have a
highly differentiated profile. Furthermore, in the most severe
cases of cardiac disease, they present markers of apoptosis,
while a minor fraction shows a long-term memory T cells
phenotype (189). This evidence favors the T cell response
exhaustion hypothesis in the context of chronic Chagas disease.
In addition, experiments in which PBMC from chronic cardiac
Chagas patients were stimulated in vitro and secreted cytokines
were analyzed showed that antigens from the parasite induce
a response profile that does not completely fit in any of the
mentioned, including TH1 (IFN-γ, TNF-α) and TH2 (IL-4, IL-
13) cytokines, along with IL-2, IL-10 and GM-CSF. GM-CSF,
IL-10, and TNF-α secretion was attributed at least partially
to the response against parasite ribosomal P proteins which,
as mentioned before, are related to humoral self-reactivity
phenomena (190).
Another subset of TH cells, TH17, contributes to response
against pathogens. Although early research on the subject
emphasized their pathogenic role, especially in autoimmune
disease or chronic inflammation models, evidence in favor
of the protective role of these cells against infection by
diverse pathogens has accumulated as well (191). They produce
cytokines IL-17A, IL-17F, IL-22 and IL-26, and chemokine
CCL20. A major proportion of these cells, often termed as
a different TH17/TH1 subset, produce IFN-γ along with IL-
17A. Their physiological relevance is still subject of controversy,
since the effects of their activity differ depending on the
contextual pathology and the experimental model of study
(180). The main function of TH17 cells are the recruitment
and activation of granulocytes/neutrophils by IL-17A-mediated
activation of colony stimulating factors, and CXCL8 on
macrophages and tissue resident cells. Meanwhile, IL-21 and
IL-22 participate on mononuclear and tissue resident cells
activation, and might therefore be involved in inducing
or maintaining a chronic inflammatory process (177, 180,
191).
It has been demonstrated that TH17 cells can exert a
potent protective function against T. cruzi infection in mice, by
activating oxidative species production in infected cells via IL-
17A, and CTL cytotoxic mechanisms via IL-21. Adoptive transfer
of TH1 or TH17 cells specific against p7, a trans-sialidase epitope
that results immunodominant in this model, was used to show
that the latter confer greater protection against the parasite than
the former (192). Although TH17 cells are markedly regulated
by IL-12 family cytokines in the murine infection (193) and
CD4+ T cells of this subset are a part of the inflammatory
infiltrates in such model (194), the functional importance of this
subpopulation has not been clarified yet. Nonetheless, it is clear
that IL-17, the hallmark cytokine of this profile, is involved in the
modulation and orchestration of the response against T. cruzi. IL-
17A and IL-17F are produced in mice upon infection (48, 195),
and deletion or depletion of these cytokines or their receptor
consistently leads, in different models, to reduced survival and
augmented tissue damage, accompanied by an enhanced pro-
inflammatory response (40, 42, 195–197). In some of these
IL-17 deficient models, decreased parasitaemia and/or tissue
parasitism is observed as well (42, 195), which suggests that this
cytokine might be playing a regulatory role, by limiting pro-
inflammatory mechanisms, but at the expense of also restraining
parasiticide effector functions. In some other models, a higher
number of parasites is found in blood (197), indicating a role
for this cytokine in controlling the infection. In addition, IL-
22, a pleiotropic cytokine mainly produced by TH17 cells, is
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secreted in response to T. cruzi infection in mice, in an IL-23-
dependent fashion, which seems to contribute to the regulation of
inflammatory cytokines (198). With regards to human patients,
the panorama is less clear: while some authors have shown that
a higher frequency of IL-17+ cells within the CD3+CD4+ subset
of PBMC is associated with milder forms of the disease (99, 199),
and a correlation of IL-17A plasma levels with better cardiac
function (200), others found increased levels of IL-17 in the sera
of patients with higher risk of sudden death (201). However, it
should be kept in mind that, as it was discussed above, TH17
are not the only cell lineage producing IL-17 in response to
T. cruzi.
Advancements in the technologies applied to the study of the
T cell biology, and knowledge generated in the last years of this
field have enabled the distinction of other functional subsets of
TH cells, such as TH9 and TH22. However, no published data is
available yet regarding their role and importance in the context
of T. cruzi infection.
Regulatory T cells (Treg) operate tolerance mechanisms
via an in trans action upon other T cells, thereby restricting
potentially pathogenic immune responses (202). Under
normal physiological conditions, they are generated mainly
by recognition of self-antigens in the thymus, and of foreign
antigens in peripheral lymphoid organs. Their regulatory
function is mediated by IL-10 and TGF-β, the inhibitory receptor
CTLA-4 and exoenzymes CD39 and CD73 (202).
Given the clinical relevance of tissue inflammation control
in chronic Chagas disease, Treg cells have been the subject of
several lines of research. Thus, it has been determined that this
lymphocyte subset is augmented in asymptomatic patients as
compared to those with cardiac or digestive symptoms (199, 203–
206). Furthermore, the existence of IL-10-producing activated
Treg cells has been demonstrated in both asymptomatic and
cardiac chronic Chagas disease patients (207), while this cytokine
shows higher serum concentration in asymptomatic patients
than in cardiac ones (208). Also, it has been suggested that
Treg cells from severe and moderate cardiac Chagas patients
have less suppressor capacity than those from asymptomatic
and mild cardiac patients, and non-infected individuals (199).
In a murine IL-10 deficient models of infection, an increased
presence of CD8+ and CD4+ T cells in inflammatory cardiac
infiltrates, albeit with the exception of Treg cells, which have
a decreased frequency (209). IL-10 knock-out infected mice
have elevated levels of IL-12, TNF-α and IFN-γ in serum,
which is associated to a reduced parasitaemia and parasite
burden, but also suffer weight loss, hypothermia and have worse
survival rate (196, 210). These conditions are ameliorated upon
administration of exogenous IL-10 (210) or TNF-α blockade
(196). In accordance, anti-GITR (211, 212) treatment of infected
mice has similar effects in the composition of these infiltrates,
and animals exhibit increased TNF-α production, increased heart
parasitism and worse survival rate (213). The production of TGF-
β, was discarded as the cause of the lack of cytokine production
observed in effector CD8+ T cells isolated from inflammatory
infiltrates in T. cruzi infected heart tissue, but it regulates the
expansion of these cells and therefore has a protective role against
cardiopathy (214, 215).
As for the specificity of CD4+ T cell response in human
T. cruzi infection, exploration has been scarce, especially when
compared to the extent to which CD8+ T cells specificity
has been studied so far. Some chronic Chagas patients show
CD4+ T cell response to TSA-1 and Tc24, two antigens
that had been tested as vaccine candidates in preclinical
animal models (216). KMP-11 contains CD4+ T cell-activating
epitopes as well, as its been proven that it induces IFN-
γ secretion and proliferation in certain T. cruzi infected
subjects (188). However, it is important to notice that these
antigens triggered a recall response in only a fraction of
the patients within the cohorts of their respective studies,
which might indicate that these proteins contain HLA-restricted
epitopes.
CONCLUDING REMARKS
Across several decades of research, a remarkable volume
of information regarding the immune response to T. cruzi
infection and its role in protection, chronicity, inflammation
and pathology has accumulated. Thanks to the development
of different experimental models and the combined effort of
researchers from diverse disciplines, many of the mechanisms
and players underlying this host-pathogen interaction have
been unveiled. The motivation behind this review was to put
together the information so far collected in an organized,
comprehensive manner, in the way of those who sort the
pieces of a jigsaw puzzle on a table, following a particular
criterion, before they set to assemble them into a sensible
picture.
It is tempting to speculate that an immune-intervention
strategy could help ameliorate (if not cure) chronically infected
patients. Besides, and given the environmental factors that
influence Chagas disease transmission, prophylactic vaccination
can be envisaged as the ultimate tool for its prevention.
Yet, these possibilities are critically hampered by our lack
of understanding of the integral panorama of immunity in
the context of T. cruzi infection. Success in translating this
enormous amount of information into concrete applications
has been scarce, and it’s urgent. In the authors’ view, the
reason behind this lies in the complexity of the parasite-host
interaction, a common factor to most protozoan infections
which can hardly be comprised by the traditional, reductionist
strategies. Most research in the field has focused on clarifying
the role and relevance of individual cell subsets or activation
profiles for controlling the infection, and their relationship with
chronic Chagas disease pathology. But these approaches do not
allow an integrative comprehension of anti-T. cruzi immunity,
especially considering the high degree of interconnection
and interdependence this system displays. In that sense,
high throughput technologies and systems biology applied to
immunology are tools that this field has just began to benefit
from, and which are expected to bring new insights into this
intricate interplay.
In conclusion, our knowledge of this matter has come a long
way, but there is a clear need for the dots to be connected
in order to drive science in the direction of making an actual
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difference for the millions of people affected by this neglected
disease.
AUTHOR CONTRIBUTIONS
GA, MG, and KG designed and implemented the review,
performed literature search, and wrote the manuscript.
All authors contributed to manuscript revision, read, and
approved the submitted version. GA designed and produced
illustrations.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2018.01929/full#supplementary-material
REFERENCES
1. Rodriguez Coura J, Albajar Viñas P. Chagas disease: a new worldwide
challenge. Nature (2010) 115:14–21. doi: 10.1038/nature09221
2. WHO. Integrating Neglected Tropical Diseases Into Global Health And
Development: 4th Edn. World Health Organisation report on neglected
tropical diseases (2017).
3. Bern C. Chagas’ disease. N Engl J Med. (2015) 373:456–66.
doi: 10.1056/NEJMra1410150
4. WHO. First Who Report on Neglected Tropical Diseases: Working to
Overcome The Global Impact of Neglected Tropical Diseases. World Health
Organisation (2010) p. 1–184.
5. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health
problem becoming a world health problem. Acta Trop. (2010) 115:14–21.
doi: 10.1016/j.actatropica.2009.11.003
6. Pérez-Molina JA, Molina I. Chagas disease. Lancet (2017) 6736:1–13.
doi: 10.1016/S0140-6736(17)31612-4
7. Stimpert KK, Montgomery SP. Physycian awareness of Chagas disease, USA.
Emerg Infect Dis. (2010) 16:871–2. doi: 10.3201/eid1605.091440
8. Carlier Y, Sosa-Estani S, Luquetti AO, Buekens P. Congenital Chagas
disease: an update. Mem Inst Oswaldo Cruz (2015) 110:363–8.
doi: 10.1590/0074-02760140405
9. Shikanai-YasudaMA, CarvalhoNB. Oral transmission of chagas disease.Clin
Infect Dis. (2012) 54:845–52. doi: 10.1093/cid/cir956
10. Kierszenbaum F. Mechanisms of pathogenesis in Chagas disease. Acta
Parasitol. (2007) 52:1–12. doi: 10.2478/s11686-006-0048-y
11. Morrot A, Villar SR, González FB, Pérez AR. Evasion and immuno-
endocrine regulation in parasite infection: two sides of the same coin in
chagas disease? Front Microbiol. (2016) 7:704. doi: 10.3389/fmicb.2016.00704
12. Cestari I, Ramirez MI. Inefficient complement system clearance
of Trypanosoma cruzi metacyclic trypomastigotes enables resistant
strains to invade eukaryotic cells. PLoS ONE (2010) 5:e9721.
doi: 10.1371/journal.pone.0009721
13. Lidani KCF, Bavia L, Ambrosio AR, de Messias-Reason IJ. The complement
system: a prey of Trypanosoma cruzi. Front Microbiol. (2017) 8:607.
doi: 10.3389/fmicb.2017.00607
14. Ramírez-Toloza G, Ferreira A. Trypanosoma cruzi evades the complement
system as an efficient strategy to survive in the mammalian host: the specific
roles of host/parasite molecules and trypanosoma cruzi calreticulin. Front
Microbiol. (2017) 8:1667. doi: 10.3389/fmicb.2017.01667
15. Ferreira V, Valck C, Sánchez G, Gingras A, Tzima S, Molina MC, et
al. The classical activation pathway of the human complement system is
specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunol.
(2004) 172:3042–50. doi: 10.4049/jimmunol.172.5.3042
16. Sosoniuk E, Vallejos G, Kenawy H, Gaboriaud C, Thielens N, Fujita T, et
al. Trypanosoma cruzi calreticulin inhibits the complement lectin pathway
activation by direct interaction with L-Ficolin.Mol Immunol. (2014) 60:80–5.
doi: 10.1016/j.molimm.2014.03.014
17. Ribeiro CH, Lynch NJ, Stover CM, Ali YM, Valck C, Noya-Leal F, et al.
Deficiency in mannose-binding lectin-associated serine protease-2 does not
increase susceptibility to Trypanosoma cruzi infection. Am J Trop Med Hyg.
(2015) 92:320–4. doi: 10.4269/ajtmh.14-0236
18. Cardoso MS, Reis-Cunha JL, Bartholomeu DC. Evasion of the immune
response by trypanosoma cruzi during acute infection. Front Immunol.
(2016) 6:659. doi: 10.3389/fimmu.2015.00659
19. Geiger A, Bossard G, Sereno D, Pissarra J, Lemesre JL, Vincendeau
P, et al. Escaping deleterious immune response in their hosts:
lessons from trypanosomatids. Front Immunol. (2016) 7:212.
doi: 10.3389/fimmu.2016.00212
20. Norris KA, Bradt B, Cooper NR, So M. Characterization of a Trypanosoma
cruzi C3 binding protein with functional and genetic similarities to
the human complement regulatory protein, decay-accelerating factor. J
Immunol. (1991) 147:2240–7.
21. Norris KA, Schrimpf JE, SzaboMJ. Identification of the gene family encoding
the 160-kilodalton Trypanosoma cruzi complement regulatory protein. Infect
Immun. (1997) 65:349–57.
22. Henrique PM, Marques T, da Silva MV, Nascentes GAN, de Oliveira
CF, Rodrigues V, et al. Correlation between the virulence of T. cruzi
strains, complement regulatory protein expression levels, and the ability
to elicit lytic antibody production. Exp Parasitol. (2016) 170:66–72.
doi: 10.1016/j.exppara.2016.09.001
23. Antwi-Baffour SS. Molecular characterisation of plasma membrane-derived
vesicles. J Biomed Sci. (2015) 22:68. doi: 10.1186/s12929-015-0174-7
24. Cestari I, Ansa-Addo E, Deolindo P, Inal JM, Ramirez MI. Trypanosoma
cruzi immune evasion mediated by host cell-derived microvesicles. J
Immunol. (2012) 188:1942–52. doi: 10.4049/jimmunol.1102053
25. Wyllie MP, Ramirez MI. Microvesicles released during the interaction
between Trypanosoma cruzi TcI and TcII strains and host blood cells inhibit
complement system and increase the infectivity of metacyclic forms of
host cells in a strain-independent process. Pathog Dis. (2017) 75:ftx077.
doi: 10.1093/femspd/ftx077
26. Dolasia K, Bisht MK, Pradhan G, Udgata A, Mukhopadhyay S. TLRs/NLRs:
shaping the landscape of host immunity. Int Rev Immunol. (2017) 37:3–19.
doi: 10.1080/08830185.2017.1397656
27. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity.
Cell (2006) 124:783–801. doi: 10.1016/j.cell.2006.02.015
28. Chen K, Xiang Y, Yao X, Liu Y, Gong W, Yoshimura T, et al. The active
contribution of Toll-like receptors to allergic airway inflammation. Int
Immunopharmacol. (2011) 11:1391–98. doi: 10.1016/j.intimp.2011.05.003
29. Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, Rodrigues
MM, et al. The endless race between Trypanosoma cruzi and host immunity:
lessons for and beyond Chagas disease. Expert Rev Mol Med. (2010) 12:e29.
doi: 10.1017/S1462399410001560
30. Oliveira AC, Peixoto JR, de Arruda LB, Campos MA, Gazzinelli
RT, Golenbock DT, et al. Expression of functional TLR4
confers proinflammatory responsiveness to Trypanosoma cruzi
glycoinositolphospholipids and higher resistance to infection with T. cruzi. J
Immunol. (2004) 173:5688–96. doi: 10.4049/jimmunol.173.9.5688
31. Campos MAS, Almeida IC, Takeuchi O, Akira S, Valente EP, Procopio
DO, et al. Activation of toll-like receptor-2 by glycosylphosphatidylinositol
anchors from a protozoan parasite. J Immunol. (2001) 167:416–23.
doi: 10.4049/jimmunol.167.1.416
32. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Sher A.
Cutting edge: TLR9 and TLR2 signaling together account for MyD88-
dependent control of parasitemia in Trypanosoma cruzi infection. J
Immunol. (2006) 177:3515–19. doi: 10.4049/jimmunol.177.6.3515
33. Caetano BC, Carmo BB, Melo MB, Cerny A, dos Santos SL, Bartholomeu
DC, et al. Requirement of UNC93B1 reveals a critical role for TLR7 in host
resistance to primary infection with Trypanosoma cruzi. J Immunol. (2011)
187:1903–11. doi: 10.4049/jimmunol.1003911
Frontiers in Immunology | www.frontiersin.org 17 August 2018 | Volume 9 | Article 1929
Acevedo et al. Immune Response in Chagas Disease
34. Pinto BF, Medeiros NI, Teixeira-Carvalho A, Eloi-Santos SM, Fontes-
Cal TCM, Rocha DA, et al. CD86 expression by monocytes influence an
immunomodulatory profile in asymptomatic patients with chronic chagas
disease. Front Immunol. (2018) 9:454. doi: 10.3389/fimmu.2018.00454
35. Hasegawa H, Mizoguchi I, Chiba Y, Ohashi M, Xu M, Yoshimoto T.
Expanding diversity in molecular structures and functions of the IL-
6/IL-12 heterodimeric cytokine family. Front Immunol. (2016) 7:479.
doi: 10.3389/fimmu.2016.00479
36. Böhme J, Roßnagel C, Jacobs T, Behrends J, Hölscher C, Erdmann H.
Epstein-Barr virus-induced gene 3 suppresses T helper type 1, type 17 and
type 2 immune responses after Trypanosoma cruzi infection and inhibits
parasite replication by interfering with alternative macrophage activation.
Immunology (2016) 147:338–48. doi: 10.1111/imm.12565
37. Müller U, Köhler G, Mossmann H, Schaub GA, Alber G, Di Santo JP, et
al. IL-12-independent IFN-gamma production by T cells in experimental
Chagas’ disease is mediated by IL-18. J Immunol. (2001) 167:3346–53.
doi: 10.4049/jimmunol.167.6.3346
38. Galvão Da Silva AP, Jacysyn JF, Abrahamsohn IDA. Resistant mice lacking
interleukin-12 become susceptible to Trypanosoma cruzi infection but fail
to mount a T helper type 2 response. Immunology (2003) 108:230–7.
doi: 10.1046/j.1365-2567.2003.01571.x
39. Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, et al. WSX-
1 is required for resistance to Trypanosoma cruzi infection by regulation
of proinflammatory cytokine production. Immunity (2003) 19:657–67.
doi: 10.1016/S1074-7613(03)00298-X
40. ErdmannH, Roßnagel C, Böhme J, Iwakura Y, Jacobs T, Schaible UE, et al. IL-
17A promotes macrophage effector mechanisms against Trypanosoma cruzi
by trapping parasites in the endolysosomal compartment. Immunobiology
(2013) 218:910–23. doi: 10.1016/j.imbio.2012.10.005
41. de Barros-Mazon S, Guariento ME, Abrahamsohn IA. IL-12 enhances
proliferation of peripheral blood mononuclear cells from Chagas’ disease
patients to Trypanosoma cruzi antigen. Immunol Lett. (1997) 57:39–45.
42. Medina TS, Oliveira GG, Silva MC. Ebi3 prevents Trypanosoma cruzi-
induced myocarditis by dampening IFN- γ -driven inflammation. Front
Immunol. (2017) 8:1213. doi: 10.3389/fimmu.2017.01213
43. Walker DM, Oghumu S, Gupta G, Mcgwire BS, Drew ME, Satoskar AR.
Mechanisms of cellular invasion by intracellular parasites. Cell Mol Life Sci.
(2014) 71:1245–63. doi: 10.1007/s00018-013-1491-1
44. Romano PS, Cueto JA, Casassa AF, Vanrell MC, Gottlieb RA, Colombo MI.
Molecular and cellular mechanisms involved in the Trypanosoma cruzi/host
cell interplay. IUBMB Life (2012) 64:387–96. doi: 10.1002/iub.1019
45. Stempin C, Giordanengo L, Gea S, Cerbán F. Alternative activation
and increase of Trypanosoma cruzi survival in murine macrophages
stimulated by cruzipain, a parasite antigen. J Leukoc Biol. (2002) 72:727–34.
doi: 10.1189/jlb.72.4.727
46. Vitelli-Avelar DM, Sathler-Avelar R, Massara RL, Borges JD, Lage PS, Lana
M, et al. Are increased frequency of macrophage-like and natural killer (NK)
cells, together with high levels of NKT and CD4+CD25high T cells balancing
activated CD8+ T cells, the key to control Chagas’ disease morbidity?
Clin Exp Immunol. (2006) 145:81–92. doi: 10.1111/j.1365-2249.2006.
03123.x
47. Chen L, Watanabe T, Watanabe H, Sendo F. Neutrophil depletion
exacerbates experimental Chagas’ disease in BALB / c, but protects
C57BL/6 mice through modulating the Th1/Th2 dichotomy in different
directions. Eur J Immunol. (2001) 31:265–75. doi: 10.1002/1521-
4141(200101)31:1<265::AID-IMMU265>3.0.CO;2-L
48. Boari JT, Vesely MCA, Bermejo DA, Ramello MC, Montes CL, Cejas H, et al.
IL-17RA signaling reduces inflammation andmortality during Trypanosoma
cruzi infection by recruiting suppressive IL-10-producing neutrophils. PLoS
Pathog. (2012) 8:e1002658. doi: 10.1371/journal.ppat.1002658
49. Luna-Gomes T, Filardy AA, Rocha JDB, Decote-Ricardo D, LaRocque-
de-Freitas IF, Morrot A, et al. Neutrophils increase or reduce parasite
burden in Trypanosoma cruzi-infected macrophages, depending on
host strain: role of neutrophil elastase. PLoS ONE (2014) 9:e90582.
doi: 10.1371/journal.pone.0090582
50. Hölscher C, Köhler G, Müller U, Schaub GA, Brombacher F, Ko G. Defective
nitric oxide effector functions lead to extreme susceptibility of Trypanosoma
cruzi -infected mice deficient in gamma interferon receptor or inducible
nitric oxide synthase defective nitric oxide effector functions lead to extreme
susceptibility. Infect Immun. (1998) 66:1208–15.
51. Silva JS, Vespa GN, Cardoso M a, Aliberti JC, Cunha FQ. Tumor
necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in
mice by inducing nitric oxide production in infected gamma interferon-
activated macrophages. tumor necrosis factor alpha mediates resistance to
Trypanosoma cruzi infection. Infect Immun. (1995) 63:4862–67.
52. Koo S, Chowdhury IH, Szczesny B, Wan X, Garg NJ. Macrophages
promote oxidative metabolism to drive Nitric Oxide generation in
response to Trypanosoma cruzi. Infect Immun. (2016) 84:3527–41.
doi: 10.1128/IAI.00809-16.Editor
53. Huang H, Chan J, Wittner M, Jelicks LA, Morris SA, Factor SM, et al.
Expression of cardiac cytokines and inducible form of nitric oxide synthase
(NOS2) in Trypanosoma cruzi-infected mice. J Mol Cell Cardiol. (1999)
31:75–88. doi: 10.1006/jmcc.1998.0848
54. Sollberger G, Tilley DO, Zychlinsky A. Neutrophil extracellular traps:
the biology of chromatin externalization. Dev Cell (2018) 44:542–53.
doi: 10.1016/j.devcel.2018.01.019
55. Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L, García-
Orozco A, Alvarado-Navarro A, Fafutis-Morris M. Neutrophil extracellular
traps and its implications in inflammation: an overview. Front Immunol.
(2017) 8:81. doi: 10.3389/fimmu.2017.00081
56. Sousa-Rocha D, Thomaz-Tobias M, Diniz LFA, Souza PSS, Pinge-Filho
P, Toledo KA. Trypanosoma cruzi and its soluble antigens induce NET
release by stimulating toll-like receptors. PLoS ONE (2015) 10:e0139569.
doi: 10.1371/journal.pone.0139569
57. Zingales B, Andrade SG, Campbell DA, Chiari E, Fernandes O, Guhl F. A
new consensus for Trypanosoma cruzi intraspecific nomenclature: second
revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz (2009)
104:1051–4. doi: 10.1590/S0074-02762009000700021
58. Da Costa TA, Silva MV, Mendes MT, Carvalho-Costa TM, Batista LR,
Lages-Silva E, et al. Immunomodulation by Trypanosoma cruzi: toward
understanding the association of dendritic cells with infecting TcI and
TcII populations. J Immunol Res. (2014) 2014:962047. doi: 10.1155/2014/
962047
59. Van Overtvelt L, Vanderheyde N, Verhasselt V, Ismaili J, De Vos L, Goldman
M, et al. Trypanosoma cruzi infects human dendritic cells and prevents their
maturation: inhibition of cytokines, HLA-DR, and costimulatory molecules.
Infect Immun. (1999) 67:4033–40.
60. Van Overtvelt L, Andrieu M, Verhasselt V, Connan F, Choppin J, Vercruysse
V, et al. Trypanosoma cruzi down-regulates lipopolysaccharide-induced
MHC class I on human dendritic cells and impairs antigen presentation
to specific CD8+ T lymphocytes. Int Immunol. (2002) 14:1135–44.
doi: 10.1093/intimm/dxf077
61. Brodskyn C, Patricio J, Oliveira R, Lobo L, Arnholdt A, Mendonça-previato
L,et al. Glycoinositolphospholipids from Trypanosoma cruzi interfere with
macrophages and dendritic cell responses. Society (2002) 70:3736–43.
doi: 10.1128/IAI.70.7.3736
62. Erdmann H, Steeg C, Koch-Nolte F, Fleischer B, Jacobs T. Sialylated
ligands on pathogenic Trypanosoma cruzi interact with Siglec-E
(sialic acid-binding Ig-like lectin-E). Cell Microbiol. (2009) 11:1600–11.
doi: 10.1111/j.1462-5822.2009.01350.x
63. Ersching J, Basso AS, Kalich VLG, Bortoluci KR, Rodrigues MM. A human
trypanosome suppresses CD8+ T cell priming by dendritic cells through the
induction of immune regulatory CD4+ Foxp3+ TCells. PLoS Pathog. (2016)
12:1–23. doi: 10.1371/journal.ppat.1005698
64. Cardillo F, Voltarelli JC, Reed SG, Silva JS. Regulation of Trypanosoma cruzi
infection in mice by gamma interferon and interleukin 10: role of NK cells.
Infect Immun. (1996) 64:128–34.
65. Lieke T, Graefe SEB, Klauenberg U, Fleischer B, Jacobs T. NK cells
contribute to the control of Trypanosoma cruzi infection by killing
free parasites by perforin-independent mechanisms NK cells contribute
to the control of Trypanosoma cruzi Infection by killing free parasites
by perforin-independent mechanisms. Infect Immun. (2004) 72:6817–25.
doi: 10.1128/IAI.72.12.6817
66. Batalla EI, Pino Martínez AM, Poncini CV, Duffy T, Schijman AG,
González Cappa SM, et al. Impairment in natural killer cells editing
of immature dendritic cells by infection with a virulent Trypanosoma
Frontiers in Immunology | www.frontiersin.org 18 August 2018 | Volume 9 | Article 1929
Acevedo et al. Immune Response in Chagas Disease
cruzi population. J Innate Immun. (2013) 5:494–504. doi: 10.1159/0003
50242
67. Lieke T, Steeg C, Graefe SEB, Fleischer B, Jacobs T. Interaction of natural
killer cells with Trypanosoma cruzi-infected fibroblasts. Clin Exp Immunol.
(2006) 145:357–64. doi: 10.1111/j.1365-2249.2006.03118.x
68. Ferreira LRP, Ferreira FM, Nakaya HI, Deng X, Cândido D da S, Campos de
Oliveira L, et al. Blood gene signatures of Chagas disease cardiomyopathy
with or without ventricular dysfunction. J Infect Dis. (2015) 3:387–95.
doi: 10.1093/infdis/jiw540
69. Guilmot A, Carlier Y, Truyens C. Differential IFN-γ production by adult
and neonatal blood CD56+ natural killer (NK) and NK-like-T cells in
response to Trypanosoma cruzi and IL-15. Parasite Immunol. (2014) 36:43–
52. doi: 10.1111/pim.12077
70. Wortel CM, Heidt S. Regulatory B cells: phenotype, function
and role in transplantation. Transpl Immunol. (2017) 41:1–9.
doi: 10.1016/j.trim.2017.02.004
71. Krautz GM, Kissinger JC, Krettli AU. The targets of the lytic antibody
response against Trypanosoma cruzi. Parasitol Today (2000) 16:31–4.
doi: 10.1016/S0169-4758(99)01581-1
72. Almeida IC, Milani SR, Gorin PA, Travassos LR. Complement-mediated
lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl
antibodies. J Immunol. (1991) 146:2394–400.
73. de Oliveira Mendes TA, Reis Cunha JL, de Almeida Lourdes R, Rodrigues
Luiz GF, Lemos LD, dos Santos ARR, et al. Identification of strain-specific
B-cell epitopes in trypanosoma cruzi using genome-scale epitope prediction
and high-throughput immunoscreening with peptide arrays. PLoS Negl Trop
Dis. (2013) 7:e2524. doi: 10.1371/journal.pntd.0002524
74. Carmona SJ, Nielsen M, Schafer-Nielsen C, Mucci J, Altcheh J, Balouz
V, et al. Towards high-throughput immunomics for infectious diseases:
use of next-generation peptide microarrays for rapid discovery and
mapping of antigenic determinants.Mol Cell Proteomics (2015) 14:1871–84.
doi: 10.1074/mcp.M114.045906
75. Kumar S, Tarleton RL. The relative contribution of antibody production and
CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite
Immunol. (1998) 20:207–16.
76. Pitcovsky TA, Buscaglia CA, Mucci J, Campetella O. A functional network of
intramolecular cross-reacting epitopes delays the elicitation of neutralizing
antibodies to Trypanosoma cruzi trans-sialidase. J Infect Dis. (2002) 186:397–
404. doi: 10.1086/341463
77. Buscaglia CA, Campo VA, Frasch ACC, Di Noia JM. Trypanosoma cruzi
surface mucins: host-dependent coat diversity. Nat Rev Microbiol. (2006)
4:229–36. doi: 10.1038/nrmicro1351
78. Zuniga E, Acosta-Rodriguez E, Merino MC, Montes C, Gruppi A. Depletion
of immature B cells during Trypanosoma cruzi infection: involvement of
myeloid cells and the cyclooxygenase pathway. Eur J Immunol. (2005)
35:1849–58. doi: 10.1002/eji.200526005
79. Acosta Rodriguez EV, Zuniga EI, Montes CL, Merino MC, Bermejo
DA, Amezcua Vesely MC, et al. Trypanosoma cruzi infection beats
the B-cell compartment favouring parasite establishment: can we strike
first? Scand J Immunol. (2007) 66:137–42. doi: 10.1111/j.1365-3083.2007.
01968.x
80. Bermejo DA, Amezcua Vesely MC, Khan M, Acosta Rodriguez EV, Montes
CL, Amezcua Vesely MC, et al. Trypanosoma cruzi infection induces a
massive extrafollicular and follicular splenic B-cell response which is a high
source of non-parasite-specific antibodies. Immunology (2011) 132:123–33.
doi: 10.1111/j.1365-2567.2010.03347.x
81. Minoprio P, Burlen O, Pereira P, Guilbert B, Andrade L, Hontebeyrie-
Joskowciz M, et al, Most B Cells in acute Trypanosoma cruzi
infection lack parasite specificity. Scand J Immunol. (1988) 28:553–61.
doi: 10.1111/j.1365-3083.1988.tb01487.x
82. Ortiz-ortiz L, Parks DE, Rodriguez M, Weigle W. Polyclonal B lymphocyte
activation during Trypanosoma cruzi infection. J Immunol. (1980) 124:121–
26.
83. Bryan MA, Guyach SE, Norris KA. Specific humoral immunity
versus polyclonal B Cell activation in Trypanosoma cruzi infection
of susceptible and resistant mice. PLoS Negl Trop Dis. (2010) 4:e733.
doi: 10.1371/journal.pntd.0000733
84. Grauert MR, Houdayer M, Hontebeyrie-Joskowciz M. Trypanosoma cruzi
infection enhances polyreactive antibody response in an acute case of human
Chagas’ disease. Clin Exp Immunol. (1993) 93:85–92.
85. Montes CL, Acosta-Rodríguez EV, Mucci J, Zuniga EI, Campetella
O, Gruppi AA Trypanosoma cruzi antigen signals CD11b+ cells to
secrete cytokines that promote polyclonal B cell proliferation and
differentiation into antibody-secreting cells. Eur J Immunol. (2006) 36:1474–
85. doi: 10.1002/eji.200535537
86. Reina-San-Martín B, Degrave W, Rougeot C, Cosson A, Chamond
N, Cordeiro-Da-Silva A, et al. A B-cell mitogen from a pathogenic
trypanosome is a eukaryotic proline racemase. Nat Med. (2000) 6:890–7.
doi: 10.1038/78651
87. Gao W, Wortis HH, Pereira MA. The Trypanosoma cruzi trans-sialidase
is a T cell-independent B cell mitogen and an inducer of non-specific Ig
secretion. Int Immunol. (2002) 14:299–308. doi: 10.1093/intimm/14.3.299
88. Bonney KM, Engman DM. Autoimmune pathogenesis of chagas heart
disease: looking back, looking ahead. Am J Pathol. (2015) 185:1537–47.
doi: 10.1016/j.ajpath.2014.12.023
89. Gironès N, Cuervo H, Fresno M. Trypanosoma cruzi-induced molecular
mimicry and Chagas’ disease. In: Oldstone MB, editor. Molecular Mimicry:
Infection-Inducing AutoimmuneDisease. Berlin; Heidelberg: Springer (2005).
p. 89–123.
90. Gómez K, Longhi S, Levin M. The genesis of anti-cardiac G protein coupled
receptor antibodies in Chagas disease In: Peter JC, editors. Immunology of
G-Protein Coupled Receptors. Kerala: Dipak Haldar, SG (2006). p. 45–63.
91. Labovsky V, Smulski C, Gómez K, Levy G, Levin M. Anti-β-adrenergic
receptor autoantibodies in patients with chronic Chagas heart disease. Clin
Exp Immunol. (2007) 140:440–9. doi: 10.1111/j.1365-2249.2007.03381.x
92. Cunha-Neto E, Teixeira PC, Fonseca SG, Bilate AM, Kalil J. Myocardial
gene and protein expression profiles after autoimmune injury in
Chagas’ disease cardiomyopathy. Autoimmun Rev. (2011) 10:163–5.
doi: 10.1016/j.autrev.2010.09.019
93. Leon JS, EngmanDM. Autoimmunity in Chagas heart disease. Int J Parasitol.
(2001) 31:555–61. doi: 10.1016/S0020-7519(01)00163-1
94. Ternynck T, Bleux C, Gregoire J, Avrameas S, Kanellopoulos LC. Comparison
between autoantibodies arising during Trypanosoma cruzi infection in mice
and natural autoantibodies. J Immunol. (1990) 144:1504–11.
95. Gorosito SerránM, Tosello Boari J, Fiocca Vernengo F, Beccaría CG, Ramello
MC, Bermejo DA, et al. Unconventional pro-inflammatory CD4+ T cell
response in B Cell-deficient mice infected with Trypanosoma cruzi. Front
Immunol. (2017) 8:1548. doi: 10.3389/fimmu.2017.01548
96. Cardillo F, Postol E, Nihei J, Aroeira LS, Nomizo A, Mengel J. B cells
modulate T cells so as to favour T helper type 1 and CD8 + T-cell responses
in the acute phase of Trypanosoma cruzi infection. Immunology (2007)
122:584–95. doi: 10.1111/j.1365-2567.2007.02677.x
97. Sullivan NL, Eickhoff CS, Sagartz J, Hoft DF. Deficiency of antigen-specific
B cells results in decreased Trypanosoma cruzi systemic but not mucosal
immunity due to CD8T cell exhaustion. J Immunol. (2015) 194:1806–18.
doi: 10.4049/jimmunol.1303163
98. Bermejo DA, Jackson SW, Gorosito-Serran M, Acosta-Rodriguez EV.
Amezcua Vesely MC, Sather BD, et al. Trypanosoma cruzi trans-sialidase
initiates a program independent of the transcription factors RORγt and Ahr
that leads to IL-17 production by activated B cells. Nat Immunol. (2013)
14:514–22. doi: 10.1038/ni.2569
99. Magalhães LMDD, Villani FNAA, Nunes M do CP, Gollob KJ, Rocha
MOCC, Dutra WO. High interleukin 17 expression is correlated with better
cardiac function in human Chagas disease. J Infect Dis. (2013) 207:661–65.
doi: 10.1093/infdis/jis724
100. Sathler-Avelar R, Lemos EM, Reis DD, Medrano-Mercado N, Araujo-Jorge
TC, Antas PRZ, et al. Phenotypic features of peripheral blood leucocytes
during early stages of human infection with Trypanosoma cruzi. Scand J
Immunol. (2003) 58:655–63. doi: 10.1111/j.1365-3083.2003.01340.x
101. Fares RCG, Correa-Oliveira R, de Araújo FF, Keesen TSL, Chaves AT, Fiuza
JA, et al. Identification of phenotypic markers of B cells from patients with
Chagas disease. Parasite Immunol. (2013) 35:214–23. doi: 10.1111/pim.12038
102. Fernández ER, Olivera GC, Quebrada Palacio LP, González MN, Hernandez-
Vasquez Y, Sirena NM, et al. Altered distribution of peripheral bloodmemory
Frontiers in Immunology | www.frontiersin.org 19 August 2018 | Volume 9 | Article 1929
Acevedo et al. Immune Response in Chagas Disease
B cells in humans chronically infected with Trypanosoma cruzi. PLoS ONE
(2014) 9:e104951. doi: 10.1371/journal.pone.0104951
103. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B
cell processing and presentation of complement-tagged antigens. J Immunol.
(2001) 167:163–72. doi: 10.4049/jimmunol.167.1.163
104. Aziz M, Holodick NE, Rothstein TL, Wang P. The role of
B-1 cells in inflammation. Immunol Res. (2015) 63:153–66.
doi: 10.1007/s12026-015-8708-3
105. Rothstein TL, Griffin DO, Holodick NE, Quach TD, Kaku H. Human
B-1 cells take the stage. Ann N Y Acad Sci. (2013) 1285:97–114.
doi: 10.1111/nyas.12137
106. Herzenberg LA. B-1 cells: the lineage question revisited. Immunol Rev. (2000)
175:9–22. doi: 10.1034/j.1600-065X.2000.017520.x
107. Minoprio P, Coutinho A, Spinella S, Hontebeyrie-joskowicz M. Xid
immunodeficiency imparts increased parasite clearance and resistance to
pathology in experimental Chagas’ disease. Int Immunol. (1991) 3:427–33.
doi: 10.1093/intimm/3.5.427
108. Minoprio P, el Cheikh MC, Murphy E, Hontebeyrie-Joskowicz M, Coffman
R, Coutinho A, O’Garra A. Xid-associated resistance to experimental Chagas’
disease is IFN-gamma dependent. J Immunol. (1993) 151:4200–8.
109. Merino MC, Montes CL, Acosta-Rodriguez EV, Bermejo DA, Amezcua
Vesely MC, Gruppi A. Peritoneum from Trypanosoma cruzi-infected mice
is a homing site of Syndecan-1 negative plasma cells which mainly
provide non-parasite-specific antibodies. Int Immunol. (2010) 22:399–410.
doi: 10.1093/intimm/dxq019
110. Amezcua Vesely MCMC, Bermejo DA, Montes CL, Acosta-Rodríguez EV.
Gruppi A. B-cell response during protozoan parasite infections. J Parasitol
Res. (2012) 2012:362131. doi: 10.1155/2012/362131
111. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function.
Immunity (2015) 42:607–12. doi: 10.1016/j.immuni.2015.04.005
112. Dai Y, Zhong J, Xu J. Regulatory B cells in infectious disease (Review). Mol
Med Rep. (2017) 16:3−10. doi: 10.3892/mmr.2017.6605
113. Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4+ T
cells in CD8+ T cell memory. Nat Rev Immunol. (2016) 16:102–11.
doi: 10.1038/nri.2015.10
114. Lewinsohn DA, Lewinsohn DM, Scriba TJ. Polyfunctional CD4+T cells
as targets for tuberculosis vaccination. Front Immunol. (2017) 8:1262.
doi: 10.3389/fimmu.2017.01262
115. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of
protection for vaccine induced immune responses. Vaccine (2012) 30:4907–
920. doi: 10.1016/j.vaccine.2012.05.049
116. Dutra WO, Gollob KJ. Current concepts in immunoregulation and
pathology of human Chagas disease. Curr Opin Infect Dis. (2008) 21:287–92.
doi: 10.1086/498510.Parasitic
117. Acevedo GR, Longhi SA, Bunying A, Sabri N, Zago P, Santos R, et al.
Methodological approach to the ex vivo expansion and detection of T. cruzi
-specific T cells from chronic Chagas disease patients. PLoS ONE (2017)
12:e0178380. doi: 10.1371/journal.pone.0178380
118. Giraldo NA, Bolaños NI, Cuellar A, Roa N, Cucunubá Z, Rosas F, et al.
T lymphocytes from Chagasic patients are activated but lack proliferative
capacity and down-regulate CD28 and CD3ζ. PLoS Negl Trop Dis. (2013)
7:e2038. doi: 10.1371/journal.pntd.0002038
119. Sartori AMC, Neto JE, Nunes EV, Braz LMA, Caiaffa HH, Oliveira OD, et
al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison
between human immunodeficiency virus (HIV)-positive and HIV-negative
patients. J Infect Dis. (2002) 872–75. doi: 10.1086/342510
120. Vaidian AK, Weiss LM, Tanowitz HB. Chagas’ disease and AIDS.
Kinetoplastid Biol Dis. (2004) 3:2. doi: 10.1186/1475-9292-3-2
121. Virgilio S, Pontes C, Dominguez MR, Ersching J, Rodrigues MM,
Vasconcelos JR, et al. CD8+ T cell-mediated immunity during Trypanosoma
cruzi infection: a path for vaccine development? Mediat Inflamm. (2014)
2014:1–12. doi: 10.1155/2014/243786
122. Pulendran B, Ahmed R. Translating innate immunity into immunological
memory: implications for vaccine development. Cell (2006) 124:849–63.
doi: 10.1016/j.cell.2006.02.019
123. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory
T cell subsets: function, generation, and maintenance. Annu Rev Immunol.
(2004) 22:745–63. doi: 10.1146/annurev.immunol.22.012703.104702
124. Lanzavecchia A, Sallusto F. Understanding the generation and function
of memory T cell subsets. Curr Opin Immunol. (2005) 17:326–32.
doi: 10.1016/j.coi.2005.04.010
125. Fiuza JA, Fujiwara RT, Gomes JAS, Rocha MODC, Chaves AT, De Araújo
FF, et al. Profile of central and effector memory T cells in the progression
of chronic human Chagas disease. PLoS Negl Trop Dis. (2009) 3:e512.
doi: 10.1371/journal.pntd.0000512
126. Wherry EJ, KurachiM.Molecular and cellular insights into T cell exhaustion.
Nat Publ Gr. (2015) 15:486–99. doi: 10.1038/nri3862
127. AndersonAC, Joller N, KuchrooVK. Lag-3, Tim-3, and TIGIT: co-inhibitory
receptors with specialized functions in immune regulation. Immunity (2016)
44:989–1004. doi: 10.1016/j.immuni.2016.05.001
128. Leavey JK, Tarleton RL. Cutting edge: dysfunctional CD8+ T cells reside
in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J
Immunol. (2003) 170:2264–8. doi: 10.4049/jimmunol.170.5.2264
129. Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Semin
Immunopathol. (2015) 37:233–38. doi: 10.1007/s00281-015-0481-9
130. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez
MG, et al. Frequency of interferon- gamma -producing T cells specific
for Trypanosoma cruzi inversely correlates with disease severity in chronic
human Chagas disease. J Infect Dis. (2004) 189:909–18. doi: 10.1086/381682
131. Albareda MC, De Rissio AM, Tomas G, Serjan A, Alvarez MG, Viotti
R, et al. Polyfunctional T cell responses in children in early stages
of chronic Trypanosoma cruzi infection contrast with monofunctional
responses of long-term infected adults. PLoS Negl Trop Dis. (2013) 7:e2575.
doi: 10.1371/journal.pntd.0002575
132. Alvarez MG, Bertocchi GL, Cooley G, Albareda MC, Viotti R, Perez-Mazliah
DE, et al. Treatment success in Trypanosoma cruzi infection is predicted by
early changes in serially monitored parasite-specific T and B cell responses.
PLoS Negl Trop Dis. (2016) 10:e0004657. doi: 10.1371/journal.pntd.0004657
133. Mateus J, Pérez-Antón E, Lasso P, Egui A, Roa N, Carrilero B,
et al. Antiparasitic treatment induces an improved CD8 + T cell
response in chronic Chagasic patients. J Immunol. (2017) 198: 3170–80.
doi: 10.4049/jimmunol.1602095
134. Castro EiroMD, AlvarezMG, Cooley G, Viotti RJ, Bertocchi GL, Lococo B, et
al. The significance of discordant serology in chagas disease: enhanced T-cell
immunity to Trypanosoma cruzi in serodiscordant subjects. Front Immunol.
(2017) 8:1141. doi: 10.3389/fimmu.2017.01141
135. Williams MA, Bevan MJ. Effector and memory CTL
differentiation. Annu Rev Immunol. (2007) 25:171–192.
doi: 10.1146/annurev.immunol.25.022106.141548
136. Kaech SM,Wherry EJ, Ahmed R. Effector and memory T-cell differentiation:
implications for vaccine development. Nat Rev Immunol. (2002) 2:251–62.
doi: 10.1038/nri778
137. Weninger W, Manjunath N, von Andrian UH. Migration and
differentiation of CD8+ T cells. Immunol Rev. (2002) 186:221–33.
doi: 10.1034/j.1600-065X.2002.18618.x
138. Hoves S, Trapani JA, Voskoboinik I. The battlefield of perforin/granzyme
cell death pathways. J Leukoc Biol. (2010) 87:237–243. doi: 10.1189/jlb.09
09608
139. Tarleton RL. Depletion of CD8+ T cells increases susceptibility and reverses
vaccine-induced immunity in mice infected with Trypanosoma cruzi. J
Immunol. (1990) 144:717–24.
140. Tarleton RL, Koller BH, Latour A, Postan M. Susceptibility of β2-
microglobulin-deficient mice to Trypanosoma cruzi infection. Nature (1992)
356:338–340.
141. Martin D, Tarleton R. Generation, specificity, and function of CD8+ T
cells in Trypanosoma cruzi infection. Immunol Rev. (2004) 201:304–17.
doi: 10.1111/j.0105-2896.2004.00183.x
142. Michailowsky V, Silva NM, Rocha CD, Vieira LQ, Lannes-Vieira J, Gazzinelli
RT. Pivotal role of interleukin-12 and interferon-γ axis in controlling
tissue parasitism and inflammation in the heart and central nervous system
during Trypanosoma cruzi infection. Am J Pathol. (2001) 159:1723–33.
doi: 10.1016/S0002-9440(10)63019-2
143. Ripoll JG, Giraldo NA, Bolaños NI, Roa N, Rosas F, Cuéllar A, et al.
T cells responding to Trypanosoma cruzi detected by membrane TNF-α
and CD154 in chagasic patients. Immunity Inflamm Dis. (2017) 6:47–57.
doi: 10.1002/iid3.197
Frontiers in Immunology | www.frontiersin.org 20 August 2018 | Volume 9 | Article 1929
Acevedo et al. Immune Response in Chagas Disease
144. Albareda MC, Laucella SA, Alvarez MG, Armenti AH, Bertochi G, Tarleton
RL, et al. Trypanosoma cruzi modulates the profile of memory CD8+ T
cells in chronic Chagas’ disease patients. Int Immunol. (2006) 18:465–71.
doi: 10.1093/intimm/dxh387
145. Tzelpis F, de Alencar B, Penido M, Gazzinelli R, Persechini P RM. Distinct
kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma
cruzi in Naive or vaccinated mice. Infect Immun. (2006) 74:2477–81.
doi: 10.1128/IAI.74.4.2477
146. Padilla AM, Bustamante JM, Tarleton RL. CD8+ T cells in
Trypanosoma cruzi infection. Curr Opin Immunol. (2009) 21:385–390.
doi: 10.1016/j.coi.2009.07.006
147. Padilla AM, Simpson LJ, Tarleton RL. Insufficient TLR activation contributes
to the slow development of CD8+ T cell responses in Trypanosoma cruzi
infection. J Immunol. (2009) 183:1245–52. doi: 10.4049/jimmunol.0901178
148. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human
memory T cell subset with stem cell – like properties. Nat Med. (2011)
17:1290–98. doi: 10.1038/nm.2446
149. Sallusto F, Lanzavecchia A.Memory in disguise.Nat Publ Gr. (2011) 17:1182–
3. doi: 10.1038/nm.2502
150. Ahmed R, Roger L, Costa del Amo P, Miners KL, Jones RE, Boelen L, et al.
Human stem cell-like memory T cells are maintained in a state of dynamic
flux. Cell Rep. (2016) 17:2811–8. doi: 10.1016/j.celrep.2016.11.037
151. Mateus J, Lasso P, Pavia P, Rosas F, Roa N, Valencia-Hernandez CA, et al. Low
frequency of circulating CD8+ T stem cell memory cells in chronic Chagasic
patients with severe forms of the disease. PLoS Negl Trop Dis. (2015) 9:e3432.
doi: 10.1371/journal.pntd.0003432
152. Appay V, Bosio A, Lokan S, Wiencek Y, Biervert C, Küsters D, et al. Sensitive
gene expression profiling of human T cell subsets reveals parallel post-
thymic differentiation for CD4+ and CD8+ Lineages. J Immunol. (2007)
179:7406–14. doi: 10.4049/jimmunol.179.11.7406
153. Costa RP, Gollob KJ, Fonseca LL, C Rocha MO, L Chaves AC, Medrano-
mercado N, et al. T-Cell repertoire analysis in acute and chronic human
Chagas’ disease: differentail frequencies of Vb5 expressing T cells. Scand J
Immunol. (2000) 51:511–9. doi: 10.1046/j.1365-3083.2000.00706.x
154. Souza PEA, Rocha MOC, Menezes CAS, Coelho JS, Chaves ACL, Gollob
KJ, et al. Trypanosoma cruzi infection induces differential modulation of
costimulatory molecules and cytokines by monocytes and T cells from
patients with indeterminate and cardiac Chagas’ disease. Infect Immun.
(2007) 75:1886–94. doi: 10.1128/IAI.01931-06
155. Argüello RJ, Albareda MC, Alvarez MG, Bertocchi G, Armenti AH, Vigliano
C, et al. Inhibitory receptors are expressed by Trypanosoma cruzi-specific
effector T cells and in hearts of subjects with chronic chagas disease. PLoS
ONE (2012) 7:e35966. doi: 10.1371/journal.pone.0035966
156. Dias FC, Medina T da S, Mendes-Junior CT, Dantas RO,
Pissetti CW, Rodrigues Junior V, et al. Polymorphic sites at the
immunoregulatory CTLA-4 gene are associated with chronic chagas
disease and its clinical manifestations. PLoS ONE (2013) 8:e78367.
doi: 10.1371/journal.pone.0078367
157. Alvarez MG, Postan M, Weatherly DB, Albareda MC, Sidney J, Sette A, et al.
HLA class I-T cell epitopes from trans-sialidase proteins reveal functionally
distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop
Dis. (2008) 2:e288. doi: 10.1371/journal.pntd.0000288
158. Martin D, Weatherly DB, Laucella SA, Cabinian MA, Crim MT, Sullivan
S, et al. CD8+ T-cell responses to Trypanosoma cruzi are highly focused
on strain-variant trans-sialidase epitopes. PLoS Pathog. (2006) 2:e77.
doi: 10.1371/journal.ppat.0020077
159. Tzelepis F, de Alencar BCG, Penido MLO, Claser C, Machado AV, Bruna-
Romero O, et al. Infection with Trypanosoma cruzi restricts the repertoire
of parasite-specific CD8+ T cells leading to immunodominance. J Immunol.
(2008) 180:1737–48. doi: 10.4049/jimmunol.180.3.1737
160. Wizel B, Nunes M, Tarleton RL. Identification of Trypanosoma cruzi trans-
sialidase family members as targets of protective CD8+ TC1 responses. J
Immunol. (1997) 159:6120–30.
161. Low HP, Santos MA, Wizel B, Tarleton RL. Amastigote surface proteins of
Trypanosoma cruzi are targets for CD8+ CTL. J Immunol. (1998) 160:1817–
23.
162. Egui A, Thomas MCC, Morell M, Marañón C, Carrilero B, Segovia
M, et al. Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain
immunodominant CD8+ T-cell epitopes that are recognized by cytotoxic
T cells from Chagas disease patients. Mol Immunol. (2012) 52:289–98.
doi: 10.1016/j.molimm.2012.05.021
163. Fonseca SG, Moins-Teisserenc H, Clave E, Ianni B, Nunes VL, Mady
C, et al. Identification of multiple HLA-A∗0201-restricted cruzipain
and FL-160 CD8+ epitopes recognized by T cells from chronically
Trypanosoma cruzi-infected patients. Microbes Infect. (2005) 7:688–97.
doi: 10.1016/j.micinf.2005.01.001
164. Fralish BH, Tarleton RL. Genetic immunization with LYT1 or a pool of
trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Vaccine (2003) 21:3070–80. doi: 10.1016/S0264-410X(03)00121-X
165. Menezes CAS, Rocha MOC, Souza PEA, Chaves ACL, Gollob KJ, Dutra
WO. Phenotypic and functional characteristics of CD28+ and CD28-
cells from chagasic patients: distinct repertoire and cytokine expression.
Clin Exp Immunol. (2004) 137:129–138. doi: 10.1111/j.1365-2249.2004.
02479.x
166. Garg N, Nunes MP, Tarleton RL. Delivery by Trypanosoma cruzi of proteins
into the MHC class I antigen processing and presentation pathway. J
Immunol. (1997) 158:3293–302.
167. Engman DM, Leon JS. Pathogenesis of Chagas heart
disease: role of autoimmunity. Acta Trop. (2002) 81:123–32.
doi: 10.1016/S0001-706X(01)00202-9
168. Scharfstein J, Gomes J de AS, Correa-Oliveira R. Back to the future in
Chagas disease: from animal models to patient cohort studies, progress in
immunopathogenesis research. Mem Inst Oswaldo Cruz (2009) 104:187–98.
doi: 10.1590/S0074-02762009000900025
169. Bonney KM, Taylor JM, Thorp EB, Epting CL, Engman DM. Depletion
of regulatory T cells decreases cardiac parasitosis and inflammation
in experimental Chagas disease. Parasitol Res. (2015) 114:1167–78.
doi: 10.1007/s00436-014-4300-3
170. Lannes-Vieira J. Trypanosoma cruzi-elicited CD8+ T cell-mediated
myocarditis: chemokine receptors and adhesion molecules as potential
therapeutic targets to control chronic inflammation? Mem Inst
Oswaldo Cruz (2003) 98:299–304. doi: 10.1590/S0074-027620030003
00002
171. da Silveira ABM, Lemos EM, Adad SJ, Correa-Oliveira R, Furness JB,
D’Avila Reis D. Megacolon in Chagas disease: a study of inflammatory
cells, enteric nerves, and glial cells. Hum Pathol. (2007) 38:1256–64.
doi: 10.1016/j.humpath.2007.01.020
172. Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena
EC, et al. Locally produced survival cytokines IL-15 and IL-7 may be
associated to the predominance of CD8+ T cells at heart lesions of human
chronic chagas disease cardiomyopathy. Scand J Immunol. (2007) 66:362–71.
doi: 10.1111/j.1365-3083.2007.01987.x
173. Dutra WO, Menezes CAS, Magalhães LMD, Gollob KJ. Immunoregulatory
networks in human Chagas disease. Parasite Immunol. (2014) 36:377–87.
doi: 10.1111/pim.12107
174. Gomes JAS, Rocha MOC, Gazzinelli G. Evidence that development of severe
cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune
response evidence that development of severe cardiomyopathy in human
Chagas’ disease is due to a Th1-specific immune response. (2003) 71:1185–
93. doi: 10.1128/IAI.71.3.1185
175. Gomes JAS, Bahia-oliveira LMG, Rocha OC, Busek SCU, Teixeira
MM, Silva JS, et al. Type 1 chemokine receptor expression in
Chagas’ disease correlates with morbidity in cardiac patients type
1 chemokine receptor expression in Chagas’ disease correlates with
morbidity in cardiac patients. (2005) 73:7960–66. doi: 10.1128/IAI.73.12.
7960
176. Dotiwala F, Mulik S, Polidoro RB, Ansara JA, Burleigh BA, Walch M,
et al. Killer lymphocytes use granulysin, perforin and granzymes to kill
intracellular parasites. Nat Med. (2016) 22:210–18. doi: 10.1038/nm.4023
177. Sallusto F. Heterogeneity of human CD4+ T Cells
against microbes. Annu Rev Immunol. (2016) 34:317–34.
doi: 10.1146/annurev-immunol-032414-112056
178. Ben Younes-Chennoufi A, Said G, Eisen H, Durand A, Hontebeyrie-
Joskowicz M. Cellular immunity to Trypanosoma cruzi is mediated by
helper T cells (CD4+). Trans R Soc Trop Med Hyg. (1988) 82:84–9.
doi: 10.1016/0035-9203(88)90271-4
Frontiers in Immunology | www.frontiersin.org 21 August 2018 | Volume 9 | Article 1929
Acevedo et al. Immune Response in Chagas Disease
179. Padilla A, Xu D, Martin D, Tarleton R. Limited role for CD4+ T-cell help
in the initial priming of Trypanosoma cruzi-specific CD8+ T cells. Infect
Immun. (2007) 75:231–5. doi: 10.1128/IAI.01245-06
180. Annunziato F, Romagnani S. Heterogeneity of human effector
CD4+ T cells. Arthritis Res Ther. (2009) 11:257. doi: 10.1186/
ar2843
181. Silva J, Morrisey P, Grabstein K, Mohler K, Anderson D, Reed S. Interleukin
10 and Interferon γ regulation of experimental Trypanosoma cruzi infection.
J Exp Med. (1992) 175:169–74.
182. Petray PB, Rottenberg ME, Bertot G, Corral RS, Diaz A, Örn A,
et al. Effect of anti-γ-interferon and anti-interleukin-4 administration
on the resistance of mice against infection with reticulotropic and
myotropic strains of Trypanosoma cruzi. Immunol Lett. (1993) 35:77–80.
doi: 10.1016/0165-2478(93)90151-Q
183. Rodrigues MM, Ribeirão M, Pereira-Chioccola V, Renia L, Costa F.
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization
of the cellular immune response generated by immunization with a
DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun. (1999)
67:3855–63.
184. Kumar S, Tarleton RL. Antigen-specific Th1 but not Th2 cells provide
protection from lethal Trypanosoma cruzi infection in mice. J Immunol.
(2001) 166:4596–603. doi: 10.4049/jimmunol.166.7.4596
185. Hoft DF, Eickhoff CS. Type 1 immunity provides both optimal mucosal and
systemic protection against a mucosally invasive, intracellular pathogen.
Infect Immun. (2005) 73:4934–40. doi: 10.1128/IAI.73.8.4934-4940.
2005
186. Díaz PR, Mucci J, Meira MA, Bogliotti Y, Musikant D, LeguizamónMS, et al.
Trypanosoma cruzi trans-sialidase prevents elicitation of Th1 cell response
via interleukin 10 and downregulates Th1 effector cells. Infect Immun. (2015)
83:2099–108. doi: 10.1128/IAI.00031-15
187. Nunes MP, Fortes B, Silva-Filho JL, Terra-Granado E, Santos L, Conde L,
et al. Inhibitory effects of Trypanosoma cruzi sialoglycoproteins on CD4+
T cells are associated with increased susceptibility to infection. PLoS ONE
(2013) 8:e77568. doi: 10.1371/journal.pone.0077568
188. Cuellar A, Rojas F, Bolãos N, Diez H, Del Carmen Thomas M, Rosas F,
et al. Natural CD4+ T-cell responses against Trypanosoma cruzi KMP-11
protein in chronic chagasic patients. Immunol Cell Biol. (2009) 87:149–53.
doi: 10.1038/icb.2008.76
189. Albareda MC, Olivera GC, Laucella SA, Alvarez MG, Fernandez ER,
Lococo B, et al. Chronic human infection with Trypanosoma cruzi drives
CD4+ T cells to immune senescence. J Immunol. (2009) 183:4103–8.
doi: 10.4049/jimmunol.0900852
190. Longhi SA, Atienza A, Prados GP, Buying A, Balouz V, Buscaglia CA,
et al. Cytokine production but lack of proliferation in peripheral blood
mononuclear cells from chronic Chagas’ disease cardiomyopathy patients
in response to T. cruzi ribosomal P proteins. PLoS Negl Trop Dis. (2014)
8:e2906. doi: 10.1371/journal.pntd.0002906
191. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector
functions of TH17 cells. Nature (2008) 453:1051–7. doi: 10.1038/nature
07036
192. Cai CW, Blase JR, Zhang X, Eickhoff CS, Hoft DF. Th17 cells are more
protective than Th1 cells against the intracellular parasite Trypanosoma
cruzi. PLoS Pathog. (2016) 12:e1005902. doi: 10.1371/journal.ppat.1005902
193. Cobb D, Smeltz RB. Regulation of proinflammatory Th17 responses during
Trypanosoma cruzi infection by IL-12 family cytokines. J Immunol. (2012)
188:3766–73. doi: 10.4049/jimmunol.1103478
194. Sanoja C, Carbajosa S, Fresno M, Gironés N. Analysis of the
dynamics of infiltrating CD4+ T cell subsets in the heart during
experimental Trypanosoma cruzi infection. PLoS ONE (2013) 8:e65820.
doi: 10.1371/journal.pone.0065820
195. Guedes PMDM, Gutierrez FRS, Maia FL, Milanezi CM, Silva GK, Pavanelli
WR, et al. IL-17 produced during Trypanosoma cruzi infection plays a central
role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis. (2010)
4:e604. doi: 10.1371/journal.pntd.0000604
196. Hölscher C, Mohrs M, Dai WJ, Ryffel B, Schaub GA, Brombacher F.
Tumor necrosis factor alpha-mediated toxic shock in Trypanosoma cruzi
-infected interleukin 10-deficient mice. Infect Immu. (2000) 68:4075–83.
doi: 10.1128/IAI.68.7.4075-4083.2000
197. Miyazaki Y, Hamano S, Wang S, Shimanoe Y, Iwakura Y, Yoshida H.
IL-17 is necessary for host protection against acute-phase Trypanosoma
cruzi infection. J Immuno. (2010) 185:1150–7. doi: 10.4049/jimmunol.09
00047
198. Erdmann H, Behrends J, Hölscher C. During acute experimental infection
with the reticulotropic Trypanosoma cruzi strain Tulahuen IL-22 is induced
IL-23-dependently but is dispensable for protection. Sci Rep. (2016) 6:32927.
doi: 10.1038/srep32927
199. Guedes PMM, Gutierrez FRS, Silva GK, Dellalibera-Joviliano R, Rodrigues
GJ, Bendhack LM, et al. Deficient regulatory T cell activity and low
frequency of IL-17-producing T cells correlate with the extent of
cardiomyopathy in human Chagas’ disease. PLoS Negl Trop Dis. (2012)
6:e1630. doi: 10.1371/journal.pntd.0001630
200. Sousa GR, Gomes JAS, Damasio MPS, Nunes MCP, Costa HS, Medeiros
NI, et al. The role of interleukin 17-mediated immune response in
Chagas disease: high level is correlated with better left ventricular
function. PLoS ONE (2017) 12:e0172833. doi: 10.1371/journal.pone.01
72833
201. Rodríguez-Angulo H, Marques J, Mendoza I, Villegas M, Mijares A,
Gironès N, et al. Differential cytokine profiling in Chagasic patients
according to their arrhythmogenic-status. BMC Infect Dis. (2017) 17:221.
doi: 10.1186/s12879-017-2324-x
202. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T Cells: mechanisms
of differentiation and function. Annu Rev Immunol. (2012) 30:531–64.
doi: 10.1146/annurev.immunol.25.022106.141623
203. Vitelli-Avelar DM, Sathler-Avelar R, Dias JCP, Pascoal VPM, Teixeira-
Carvalho A, Lage PS, et al. Chagasic patients with indeterminate clinical
form of the disease have high frequencies of circulating CD3+CD16 -CD56
+ natural killer T cells and CD4 +CD25 High regulatory T lymphocytes.
Scand J Immunol. (2005) 62:297–308. doi: 10.1111/j.1365-3083.2005.
01668.x
204. da Silveira ABMM, Fortes de Araújo F, Freitas MARR, Gomes JAS,
Chaves AT, de Oliveira EC, et al. Characterization of the presence
and distribution of Foxp3+cells in chagasic patients with and without
megacolon. Hum Immunol. (2009) 70:65–7. doi: 10.1016/j.humimm.2008.
10.015
205. de Araújo FF, Corrêa-Oliveira R, Rocha MOC, Chaves AT, Fiuza JA,
Fares RCG, et al. Foxp3+CD25highCD4+regulatory T cells from
indeterminate patients with Chagas disease can suppress the effector
cells and cytokines and reveal altered correlations with disease
severity. Immunobiology (2012) 217:768–77. doi: 10.1016/j.imbio.2012.
04.008
206. Laucella SA, Riarte A, Prado N, Zapata J, Segura EL. α4 integrins and
sialyl Lewis x modulation in chronic chagas disease: further evidence
of persistent immune activation. Scand J Immunol. (2001) 53:514–9.
doi: 10.1046/j.1365-3083.2001.00916.x
207. de Araújo FF, Vitelli-Avelar DM, Teixeira-Carvalho A, Antas PRZ, Gomes
JAS, Sathler-Avelar R, et al. Regulatory T cells phenotype in different
clinical forms of chagas’ disease. PLoS Negl Trop Dis. (2011) 5:e992.
doi: 10.1371/journal.pntd.0000992
208. Sousa GR, Gomes JAS, Fares RCG, Damásio MPDS, Chaves AT,
Ferreira KS, et al. Plasma cytokine expression is associated with
cardiac morbidity in chagas disease. PLoS ONE (2014) 9:e87082.
doi: 10.1371/journal.pone.0087082
209. Roffe E, Rothfuchs AG, Santiago HC, Marino APMP, Ribeiro-Gomes FL,
Eckhaus M, et al. IL-10 limits parasite burden and protects against fatal
myocarditis in a mouse model of Trypanosoma cruzi Infection. J Immunol.
(2012) 188:649–60. doi: 10.4049/jimmunol.1003845
210. Hunter CA, Ellis-Neyes LA, Slifer T, Kanaly S, Grünig G, Fort M. IL-
10 is required to prevent immune hyperactivity during infection with
Trypanosoma cruzi. J Immunol (1997) 158:3311–6.
211. Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR
cancer immunotherapy. Eur J Cancer (2016) 67:1–10.
doi: 10.1016/j.ejca.2016.06.028
212. Snell LM, Lin GHY, McPherson AJ, Moraes TJ, Watts TH. T-cell intrinsic
effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Immunol Rev. (2011) 244:197–217. doi: 10.1111/j.1600-065X.2011.
01063.x
Frontiers in Immunology | www.frontiersin.org 22 August 2018 | Volume 9 | Article 1929
Acevedo et al. Immune Response in Chagas Disease
213. Mariano FS, Gutierrez FRS, Pavanelli WR, Milanezi CM, Cavassani
KA, Moreira AP, et al. The involvement of CD4+CD25+
T cells in the acute phase of Trypanosoma cruzi infection.
Microb Infect. (2008) 10:825–33. doi: 10.1016/j.micinf.2008.
04.009
214. Kotner J, Tarleton R. Endogenous CD4+ CD25+ regulatory T cells have a
limited role in the control of Trypanosoma cruzi infection in mice. Infect
Immun. (2007) 75:861–9. doi: 10.1128/IAI.01500-06
215. Martin DL, Postan M, Lucas P, Gress R, Tarleton RL. TGF-β regulates
pathology but not tissue CD8+ T cell dysfunction during experimental
Trypanosoma cruzi infection. Eur J Immunol. (2007) 37:2764–71.
doi: 10.1002/eji.200737033
216. Villanueva-Lizama LE, Cruz-Chan JV, Aguilar-Cetina A del C,
Herrera-Sanchez LF, Rodriguez-Perez JM, Rosado-Vallado ME, et
al. Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-
1 recall memory immune response associated with HLA-A and
-B supertypes in Chagasic chronic patients from Mexico. PLoS
Negl Trop Dis. (2018) 12:e0006240. doi: 10.1371/journal.pntd.00
06240
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer AP declared a shared affiliation, though no other collaboration, with
the authors to the handling Editor.
Copyright © 2018 Acevedo, Girard and Gómez. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 23 August 2018 | Volume 9 | Article 1929
